Skystar Bio-pharmaceutical (SKBI) 10-Q 15 May 14 2014 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2014	9-May-14
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'SKBI	'
Entity Common Stock, Shares Outstanding	'	7,604,800
Entity Registrant Name	'SKYSTAR BIO-PHARMACEUTICAL CO	'
Entity Central Index Key	'0001076939	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS(USD ($))	Mar. 31, 2014	Dec. 31, 2013
CURRENT ASSETS:	'	'
Cash	$6,848,905	$8,142,296
Accounts receivable, net of allowance for doubtful accounts of $960,578 (Unaudited) and $602,243 as of March 31, 2014 and December 31, 2013, respectively	12,663,549	11,009,498
Inventories	25,265,783	25,903,586
Deposits, prepaid expenses and other receivables	1,608,405	2,134,163
Prepayments to suppliers	40,541,475	41,061,144
Loans receivable	1,046,835	0
Deferred tax assets	403,372	364,425
Total current assets	88,378,324	88,615,112
PROPERTY, PLANT AND EQUIPMENT, NET	30,417,653	28,269,155
CONSTRUCTION-IN-PROGRESS	6,470,772	9,284,947
OTHER ASSETS:	'	'
Long-term prepayments	4,592,751	4,633,614
Long-term prepayments for acquisitions	0	183,344
Intangible assets, net	5,130,454	5,237,255
Total other assets	9,723,205	10,054,213
Total assets	134,989,954	136,223,427
CURRENT LIABILITIES:	'	'
Accounts payable	4,615,614	3,303,531
Other payable and accrued expenses	6,551,419	6,467,605
Short-term loans	5,680,500	10,640,500
Deposits from customers	1,991,907	1,877,211
Taxes payable	2,852,844	1,315,486
Due to related parties	1,962,238	1,361,548
Total current liabilities	23,654,522	24,965,881
OTHER LIABILITIES:	'	'
Deferred government grant	795,270	802,130
Purchase option liability	78,960	62,440
Total other liabilities	874,230	864,570
Total liabilities	24,528,752	25,830,451
COMMITMENTS AND CONTINGENCIES	'	'
SHAREHOLDERS' EQUITY	'	'
Preferred stock, $0.001 par value, 50,000,000 shares authorized, No Series “A” shares authorized. 48,000,000 Series “B” shares authorized. No Series “B” shares issued and outstanding	0	0
Common stock, $0.001 par value, 40,000,000 shares authorized, 7,604,800 shares issued and outstanding as of March 31, 2014 (Unaudited) and December 31, 2013	7,605	7,605
Paid-in capital	37,690,867	37,631,142
Statutory reserves	5,952,692	5,952,692
Retained earnings	55,965,604	54,990,154
Accumulated other comprehensive income	10,844,434	11,811,383
Total shareholders’ equity	110,461,202	110,392,976
Total liabilities and shareholders’ equity	$134,989,954	$136,223,427

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Mar. 31, 2014	Dec. 31, 2013
Allowance for doubtful accounts	$960,578	$602,243
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	50,000,000	50,000,000
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	7,604,800	7,604,800
Common stock, shares outstanding	7,604,800	7,604,800
Series A Preferred Stock [Member]	'	'
Preferred stock, shares authorized	0	0
Series B Preferred Stock [Member]	'	'
Preferred stock, shares authorized	48,000,000	48,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
REVENUE, net	$6,832,588	$5,530,741
COST OF REVENUE	4,009,403	2,930,886
GROSS PROFIT	2,823,185	2,599,855
OPERATING EXPENSES:	'	'
Research and development costs	4,213	461
Selling expenses	370,208	317,836
General and administrative expenses	1,276,417	1,211,273
Total operating expenses	1,650,838	1,529,570
INCOME FROM OPERATIONS	1,172,347	1,070,285
OTHER INCOME (EXPENSE):	'	'
Other income (expense), net	154,919	-187
Interest income	170,665	148,845
Interest expense	-75,934	-189,392
Change in fair value of purchase option liability	-16,520	4,466
Total other income (expense), net	233,130	-36,268
INCOME BEFORE PROVISION FOR INCOME TAXES	1,405,477	1,034,017
PROVISION FOR INCOME TAXES	430,027	321,284
NET INCOME	975,450	712,733
OTHER COMPREHENSIVE INCOME:	'	'
Foreign currency translation adjustment	-966,949	550,883
COMPREHENSIVE INCOME	$8,501	$1,263,616
EARNINGS PER SHARE:	'	'
Basic (in dollars per share)	$0.13	$0.09
Diluted (in dollars per share)	$0.13	$0.09
WEIGHTED AVERAGE NUMBER OF COMMON SHARES:	'	'
Basic (in shares)	7,676,268	7,613,712
Diluted (in shares)	7,700,734	7,613,712

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(USD ($))	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net income	$975,450	$712,733
Adjustments to reconcile net income to net cash (used in) provided by operating activities:	'	'
Depreciation	400,291	313,561
Amortization	62,477	60,872
Provision for doubtful accounts	366,218	351,534
Share based compensation	59,725	4,340
Change in fair value of purchase option liability	16,520	-4,466
Deferred tax assets	-42,380	0
Change in operating assets and liabilities	'	'
Accounts receivable	-2,127,566	-1,725,889
Inventories	419,398	-557,269
Deposits, prepaid expenses and other receivables	513,005	292,476
Prepayments to suppliers	169,771	-9,696,136
Accounts payable	1,350,410	1,023,288
Other payables and accrued expenses	135,167	-339,030
Deferred government grants	0	-159,320
Deposits from customers	131,733	28,061
Taxes payable	1,560,250	-288,655
Due to related parties	606,813	201,325
Net cash provided by (used in) operating activities	4,597,282	-9,782,575
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Refund of long-term prepayments	184,387	0
Loans to third parties	-1,054,704	0
Payments on construction-in-progress	-53,195	0
Net cash used in investing activities	-923,512	0
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Proceeds from short-term loans	0	4,779,600
Repayment of short-term loans	-4,905,600	-2,389,800
Net cash (used in) provided by financing activities	-4,905,600	2,389,800
EFFECT OF EXCHANGE RATE CHANGES ON CASH	-61,561	50,421
DECREASE IN CASH	-1,293,391	-7,342,354
CASH, beginning of period	8,142,296	11,321,848
CASH, end of period	6,848,905	3,979,494
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:	'	'
Cash paid for income tax	0	0
Cash paid for interest	129,129	181,426
Non-cash investing activities	'	'
Construction-in-progress transferred to property, plant and equipment	$2,787,566	$0

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (USD $)	Total	Common Stock [Member]	Paid-in Capital [Member]	Retained earnings Statutory reserves [Member]	Retained earnings Unrestricted [Member]	Accumulated other comprehensive income [Member]
BALANCE at Dec. 31, 2013	$110,392,976	$7,605	$37,631,142	$5,952,692	$54,990,154	$11,811,383
BALANCE (in shares) at Dec. 31, 2013	'	7,604,800	'	'	'	'
Foreign currency translation	-966,949	0	0	0	0	-966,949
Share based compensation	59,725	0	59,725	0	0	0
Net income	975,450	0	0	0	975,450	0
BALANCE at Mar. 31, 2014	$110,461,202	$7,605	$37,690,867	$5,952,692	$55,965,604	$10,844,434
BALANCE (in shares) at Mar. 31, 2014	'	7,604,800	'	'	'	'

ORGANIZATION

ORGANIZATION	3 Months Ended
	Mar. 31, 2014
Organization, Consolidation and Presentation Of Financial Statements [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'
	Note 1 - ORGANIZATION
	Organization and description of business
	Skystar Bio-Pharmaceutical Company (“Skystar” or the “Company”) was incorporated in Nevada on September 24, 1998. Since its acquisition on November 7, 2005 of Skystar Bio-Pharmaceutical (Cayman) Holdings Co., Ltd. (“Skystar Cayman”), a Cayman Islands company, the Company has been engaged in the research, development, production, marketing, and sales of veterinary healthcare and medical care products.
	All current operations of the Company are in the People’s Republic of China (“China” or the “PRC”).
	All of the Company’s operations are carried out by its subsidiaries in China and Xi’an Tianxing Bio-Pharmaceutical Co., Limited (“Xi’an Tianxing”), a PRC joint stock company that the Company controls through contractual arrangements originally between Skystar Cayman and Xi’an Tianxing. On March 10, 2008, the Company entered into a series of agreements transferring all of the rights and obligations of Skystar Cayman under the contractual arrangements to Sida Biotechnology (Xi’an) Co., Ltd. (“Sida”), a PRC company. Sida is the wholly owned subsidiary of Fortunate Time International Limited (“Fortunate Time”), a Hong Kong company and wholly owned subsidiary of Skystar Cayman. Xi’an Tianxing also has a wholly owned subsidiary, Shanghai Siqiang Biotechnological Co., Ltd. (“Shanghai Siqiang”), a PRC company.
	On September 18, 2009, Skystar Bio-Pharmaceutical Inc. (“Skystar California”) was incorporated in California and became a wholly owned subsidiary of Skystar. On December 20, 2010, Skystar California was dissolved.
	On April 21, 2010, Kunshan Sikeda Biotechnology Co., Ltd. (“Kunshan Sikeda”) was incorporated in Kunshan, Jiangsu Province, China with a registered capital of $81,150 (RMB 500,000), of which Xi’an Tianxing and Sida each contributed $40,575 (RMB 250,000). Kunshan Sikeda is jointly owned by Xi’an Tianxing and Sida. On July 31, 2013, Kunshan Sikeda was dissolved.
	On May 7, 2010, Fortunate Time formed Skystar Biotechnology (Kunshan) Co., Limited (“Skystar Kunshan”) in Kunshan, Jiangsu Province, China with a registered capital of $15,000,000, of which $2,250,000 was paid by Fortunate Time in cash. On March 26, 2014, the Company received the government approval of extension for payment of the remaining registered capital of $12,750,000 by May 6, 2015. Skystar Kunshan was formed in connection with an acquisition of assets to meet part of the registered capital requirements, and was intended to be a micro-organism manufacturing facility for the Company once the acquisition was complete. The asset acquisition was completed in September 2011.
	On August 11, 2010, Sida became the parent company of Skystar Biotechnology (Jingzhou) Co., Limited (“Skystar Jingzhou”), a company established in Jingzhou, Hubei Province, China on February 5, 2010, with registered capital of approximately $4.2 million (RMB 26,000,000) paid by Sida.
	On March 15, 2011, Xi’an Tianxing formed Xi’an Sikaida Bio-products Co., Ltd. (“Xi’an Sikaida”) with a registered capital of approximately $1,623,000 (RMB 10,000,000 ) paid by Xi’an Tianxing.
	Hereinafter, Skystar, Skystar Cayman, Fortunate Time, Sida, Xi’an Tianxing, Skystar Kunshan, Skystar Jingzhou, Shanghai Siqiang, and Xi’an Sikaida are sometimes collectively referred to as the “Company”.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	Note 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles (“U.S. GAAP”) applicable to interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (which include all significant normal and recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for all periods presented have been made. The accompanying results of operations are not necessarily indicative of the operating results that may be expected for the entire year ending December 31, 2014. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and accompanying notes thereto of the Company, which are included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013 filed with the Securities and Exchange Commission (“SEC”).
	Principles of consolidation
	The accompanying condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. The consolidated financial statements include the financial statements of the Company, its wholly-owned subsidiaries, and its variable interest entities (“VIEs”).  All significant inter-company transactions and balances between the Company, its subsidiaries, and its VIEs have been eliminated in consolidation.
	The Company has evaluated the relationship with Xi’an Tianxing and Xi’an Tianxing’s wholly owned subsidiaries, Xi’an Sikaida and Shanghai Siqiang. As a result of the contractual arrangements which obligate Sida to absorb all of the risk of loss from Xi’an Tianxing’s activities and enable Sida to receive all of its expected residual returns, the Company is the primary beneficiary of these VIEs and thus it accounts for Xi’an Tianxing, Xi’an Sikaida and Shanghai Siqiang as VIEs under the Financial Accounting Standards Board’s (“FASB”) interpretation on consolidation of variable interest entities. Accordingly, the Company consolidates the results, assets, and liabilities of Xi’an Tianxing, Xi’an Sikaida and Shanghai Siqiang.
	Use of estimates
	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The level of uncertainty in estimates and assumptions increases with the length of time to complete the underlying transactions. Actual results may differ from these estimates in amounts that may be material to the consolidated financial statements and accompanying notes. Significant estimates and assumptions made by the Company are used for, but not limited to the allowance for doubtful accounts, useful lives of property, plant and equipment and intangible assets, assumptions used in assessing impairment for long-lived assets and the fair value for derivative instruments.
	Foreign currency translation
	The Company uses the United States dollar (“U.S. dollar”) for financial reporting purposes and the Chinese Renminbi (“RMB”) as its functional currency. The Company’s subsidiaries and VIEs maintain their books and records in their functional currency, being the primary currency of the economic environment in which their operations are conducted.
	The Company translates the subsidiaries’ and VIEs’ assets and liabilities into U.S. dollars using the applicable exchange rates prevailing at the balance sheet dates, and the statements of comprehensive income and cash flows are translated at average exchange rates during the reporting period. As a result, amounts related to assets and liabilities reported on the consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets. Equity accounts are translated at historical rates. Adjustments resulting from the translation of the subsidiaries’ and VIEs’ financial statements are recorded as accumulated other comprehensive income.
	The quotation of the exchange rates does not imply free convertibility of RMB to other foreign currencies. All foreign exchange transactions continue to take place either through the People’s Bank of China or other banks authorized to buy and sell foreign currencies at the exchange rate quoted by the People’s Bank of China.
	Approval of foreign currency payments by the People’s Bank of China or other institutions requires submitting a payment application form together with invoices, shipping documents, and signed contracts. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in the results of operations as incurred.
	Fair values of financial instruments
	ASC Topic 820, Fair Value Measurement and Disclosures , defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This topic also establishes a fair value hierarchy, which requires classification based on observable and unobservable inputs when measuring fair value. Certain current assets and current liabilities are financial instruments.  Management believes their carrying amounts are a reasonable estimate of fair value because of the short period of time between the origination of such instruments and their expected realization and, if applicable, their current interest rates are equivalent to interest rates currently available. The three levels of valuation hierarchy are defined as follows:
		¨	Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
		¨	Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.
		¨	Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.
	The following table sets forth by level within the fair value hierarchy our financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2014 and December 31, 2013:
			Carrying		Fair Value Measurement at
			Value at		March 31, 2014
			March 31,
			2014		Level 1		Level 2		Level 3
	Purchase option liability		$	78,960	$	—	$	78,960	$	—
			Carrying		Fair Value Measurement at
			Value at		December 31, 2013
			December 31,
			2013		Level 1		Level 2		Level 3
	Purchase option liability		$	62,440	$	—	$	62,440	$	—
	Below is the reconciliation for the purchase option liability changes from January 1, 2014 to March 31, 2014:
	Balance, January 1, 2014		$	62,440
	Change in fair value			16,520
	Balance, March 31, 2014		$	78,960
	Revenue recognition
	Revenue of the Company is primarily derived from the sales of veterinary healthcare and medical care products in China. Sales are recognized when the following four revenue criteria are met: persuasive evidence of an arrangement exists, delivery has occurred, the selling price is fixed or determinable, and collectability is reasonably assured. Sales are presented net of value added tax (“VAT”). No estimated allowance for sales returns is reflected in these consolidated financial statements as sales returns historically have been insignificant.
	There are two types of sales upon which revenue is recognized:
		a.	Credit sales: revenue is recognized when the products have been delivered to the customers.
		b.	Full payment before delivery: Cash received is recorded as “deposits from customers” and revenue is recognized when the products have been delivered to the customers.
	Cash
	Cash includes currency on hand and demand deposits with banks with an original maturity of three months or less.
	Accounts receivable
	Accounts receivable are stated at cost, net of an allowance for doubtful accounts. The Company maintains allowances for doubtful accounts for estimated losses, if any, resulting from the failure of customers to make required payments. The Company reviews the accounts receivable on a periodic basis and makes allowances where there is doubt as to the collectibility of individual balances. In evaluating the collectibility of individual receivable balances, the Company considers many factors, including the age of the balance, the customer’s payment history, its current credit-worthiness and current economic trends.
	Inventories
	Inventories are stated at the lower of cost as determined on a weighted-average basis, or market. Inventories include purchases and related costs incurred in bringing the inventories to their present location and condition. Management reviews inventories for obsolescence and cost in excess of net realizable value and records a write-down against the inventory and additional cost of goods sold when the carrying value exceeds net realizable value.
	Property, plant and equipment
	Property, plant and equipment are stated at cost less accumulated depreciation and impairment losses, if any. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Expenditures for maintenance and repairs that do not improve or extend the useful lives of the assets are charged to operations as incurred, while renewals and betterments are capitalized. Gains and losses on disposals are included in the results of operations. Estimated useful lives of the assets are as follows:
			Estimated useful life
	Buildings and improvements		Shorter of lease
			term or 10-40 years
	Machinery and equipment		5-10 years
	Office equipment and furniture		3-10 years
	Vehicles		5-10 years
	Management assesses the carrying value of property, plant and equipment annually or more often when factors indicating impairment are present, and reduces the carrying value of such assets by the amount of the impairment. The Company determines the existence of such impairment by measuring the expected future cash flows (undiscounted) and comparing such amount to the net asset carrying value. An impairment loss, if it exists, is measured as the amount by which the carrying amount of the asset exceeds the fair value of the asset. Based on its review, management believes that, as of March 31, 2014 and December 31, 2013, there was no impairment of its property, plant and equipment.
	Construction-in-progress
	Construction-in-progress includes direct costs of construction of factory buildings. Interest incurred during the period of construction, if significant, is capitalized. All other interest is expensed as incurred. Construction-in-progress is not depreciated until such time as the asset is completed and put into service.
	Intangible assets
	Land use rights — Land use rights represent the amounts paid to acquire a long-term interest to utilize the land underlying the Company’s facilities. This type of arrangement is common for the use of land in the PRC. Land use rights are amortized on the straight-line method over the contractual lease terms.  The land use right granted to the Company’s Huxian facility was for 50 years.  The land use right granted to the Company’s Jingzhou facility was 30 years. The land use right granted to the Company’s Kunshan facility was for 41 years.
	Technological know-how — Purchased technological know-how includes confidential formulas, manufacturing processes, and technical and procedural manuals, and is amortized using the straight-line method over an estimated useful life of between five to eleven years that reflects the period over which such confidential formulas, manufacturing processes, and technical and procedural manuals are kept confidential by the Company as agreed between the Company and the selling parties.
	Impairment of intangible assets —Intangible assets are evaluated at least annually for impairment if events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Based on the existence of one or more indicators of impairment, the Company measures any impairment of long-lived assets by comparing the asset's estimated fair value with its carrying value, based on cash flow methodology. Based on its review, the Company believes that, as of March 31, 2014 and December 31, 2013, there was no impairment of its intangible assets.
	Comprehensive income
	Comprehensive income is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income is comprised of the foreign currency translation adjustments.
	Shipping and handling costs
	Shipping and handling costs related to costs of goods sold are included in selling expenses, and totaled $192,048 and $203,849 for the three months ended March 31, 2014 and 2013, respectively.
Advertising costs
Advertising costs are charged to selling expenses as incurred. Advertising costs were insignificant for both the quarters ended March 31, 2014 and 2013, respectively.
Research and development costs
Research and development costs are charged to expense as incurred and include salaries, professional fees, and technical support fees related to such efforts.
Income taxes
The Company accounts for income taxes using an asset and liability method.  Under this method, deferred income taxes are recognized for the tax consequences of temporary differences by applying enacted statutory tax rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. The effect on deferred income taxes of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or all of a deferred tax asset will not be realized.
A tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. As of March 31, 2014 and December 31, 2013, there are no unrecognized tax benefits, and the Company does not expect a significant change in tax benefits in the next 12 months.  Penalties and interest levied by taxing authorities, if any, are classified as income tax expense in the year incurred.  No significant penalties or interest relating to income taxes have been incurred during the three months ended March 31, 2014 and 2013.
According to the PRC Tax Administration and Collection Law, the statute of limitations is three years if the underpayment of taxes is due to computational or other errors made by the taxpayer or the withholding agent.  The statute of limitations extends to five years under special circumstances. In the case of transfer pricing issues, the statute of limitations is ten years. There is no statute of limitations in the case of tax evasion. Accordingly, the income tax returns of the Company’s PRC operating subsidiaries for the years ended December 31, 2008 through 2013 are open to examination by the PRC state and local tax authorities.
Government grants
The Company’s subsidiaries in China receive government subsidies from local Chinese government agencies in accordance with relevant Chinese government policies. In general, the Company presents the government subsidies received as part of other income unless the subsidies received are earmarked to compensate for a specific expense, which have been accounted for by offsetting the specific expense, such as research and development expense or interest expenses. Unearned government subsidies received are deferred for recognition until the criteria for such recognition could be met.
For research and development expenses, the Company matches and offsets the government grants with the expenses of the research and development activities as specified in the grant approval document in the corresponding period when such expenses are incurred.
No government grants were offset against the finance costs for the three months ended March 31, 2014 and 2013.
Government grants of $154,902 and $nil were received and recognized as other income during the three months ended March 31, 2014 and 2013.
Stock-based compensation
The Company records and reports stock-based compensation by measuring the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which services are received. Stock compensation for stock granted to non-employees is determined as the fair value of the consideration received or the fair value of equity instruments issued, whichever is more reliably measured.
Earnings per share
Basic earnings per share is based upon the weighted-average number of common shares outstanding. Diluted earnings per share is based on the assumption that all dilutive convertible shares, including convertible preferred shares, warrants and stock options were converted or exercised. Further, the method requires that stock dividends or stock splits be accounted for retroactively if the stock dividends or stock splits occur during the period or after the end of the period but before the release of the financial statements, by considering it outstanding for the entirety of each period presented. Diluted earnings per share is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period.
Related parties
Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of such principal owners and management, and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.
Operating segments
While the chief operating decision-makers monitor the revenue streams of the various products lines, operations are managed and financial performance is evaluated on a Company-wide basis. Product lines are aggregated into one as operating results for all product lines are similar. Accordingly, all of the major product lines (micro-organism, veterinary medicine, feed additives and vaccines) are considered by management to be aggregated in one reportable operating segment.
As the Company primarily generates its revenues from customers in the PRC, no geographical segments are presented.
Reclassification
Certain amounts included in the 2013 consolidated statements of comprehensive income has been reclassified to conform to the 2014 financial statement presentation as follows;
The Company has separately presented interest income of $148,845 on the face of consolidated statements of comprehensive income for the period ended March 31, 2013, instead of presenting it net of interest expenses.
As a result of such reclassification, interest expense, net for the three months ended March 31, 2014, has changed from $40,547 to $189,392.
The change in due to related parties of $201,325 was classified into cash flows from financing activities in the Company’s condensed consolidated statements of cash flows for the three months ended March 31, 2013. The Company has reclassified this amount as component of cash flows to operating activities.
As a result of such reclassification, net cash provided by financing activities for the three months ended March 31, 2013 has changed from $2,591,125 to $2,389,800 and net cash used in operating activities has changed from $9,983,900 to $9,782,575.
Recently issued accounting pronouncements
In March 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2013-05, Foreign Currency Matters, (Topic 830): Parent's Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity (ASU 2013-05), to resolve a diversity in accounting for the cumulative translation adjustment of foreign currency upon derecognition of a foreign subsidiary or group of assets. ASU 2013-05 requires the parent to apply the guidance in Subtopic 830-30 to release any related cumulative translation adjustment into net income when a reporting entity (parent) ceases to have a controlling financial interest in a subsidiary or group of assets within a foreign entity. Accordingly, the cumulative translation adjustment should be released into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided. Further, ASU 2013-05 clarified that the parent should apply the guidance in subtopic 810-10 if there is a sale of an investment in a foreign entity, including both (1) events that result in the loss of a controlling financial interest in a foreign entity and (2) events that result in an acquirer obtaining control of an acquiree in which it held an equity interest immediately before the acquisition date. Accordingly, the cumulative translation adjustment should be released into net income upon the occurrence of those events. The Company adopted ASU 2013-05 prospectively in its first quarter of fiscal 2014, and it did not have a significant impact on its consolidated results of operations and financial condition.
In July 2013, the FASB issued Accounting Standards Update No. 2013-11, Income Taxes (Topic 740) (ASU 2013-11). The amendments in this update provide guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, similar tax loss, or tax credit carryforward exists. These amendments provide that an unrecognized tax benefit, or a portion thereof, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except to the extent that a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date to settle any additional income taxes that would result from disallowance of a tax position, or the tax law does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, then the unrecognized tax benefit should be presented as a liability. The amendments in this update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption is permitted. The Company adopted ASU 2013-11 effective January 1, 2014 and it did not have a significant impact on its consolidated results of operations and financial condition.
Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s consolidated financial statements upon adoption.

CONCENTRATIONS_AND_CREDIT_RISK

CONCENTRATIONS AND CREDIT RISK	3 Months Ended
	Mar. 31, 2014
Risks and Uncertainties [Abstract]	'
Concentration Risk Disclosure [Text Block]	'
	Note 3 - CONCENTRATIONS AND CREDIT RISK
	The Company’s operations are all carried out in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by the political, economic, and legal environments in the PRC, and by the general state of the PRC’s economy. The Company’s operations in the PRC are subject to specific considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic, and legal environments and foreign currency exchange. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.
	Financial instruments which subject the Company to concentration of credit risk consist of cash and accounts receivable, prepayments to suppliers and others. Balances at financial institutions or state-owned banks within the PRC are not covered by insurance. The Company has not experienced any losses in such accounts. The Company provides unsecured credit terms for sales to customers and places unsecured prepayments for purchase to suppliers. As a result, there are credit risks with the accounts receivable and prepayments to suppliers .
	For the three months ended March 31, 2014 and 2013, all of the Company’s sales occurred in the PRC. No major customers accounted for more than 10% of the Company’s total revenues. All accounts receivable at March 31, 2014 and December 31, 2013 are from customers located in the PRC.
	The Company’s six largest vendors accounted for approximately 71% and 72% of the Company’s total purchases, respectively, for the three months ended March 31, 2014 and 2013, respectively. No other vendors accounted for more than 10% of the Company’s total purchases. As of March 31, 2014 and December 31, 2013, prepayments of $32,801,071 and $32,094,767 were made to the six largest vendors, respectively, for raw materials and packing materials purchases.
	The Company had one product that accounted for 32% and 16% of the Company’s total revenues for the three months ended March 31, 2014 and 2013, respectively. No other products accounted for more than 10% of the Company’s total sales.

ACCOUNTS_RECEIVABLE_NET

ACCOUNTS RECEIVABLE, NET	3 Months Ended
	Mar. 31, 2014
Accounts Receivable Disclosure [Abstract]	'
Accounts Receivable Disclosure [Text Block]	'
	Note 4 - ACCOUNTS RECEIVABLE, NET
	Accounts receivable consisted of the following:
		March 31,		December 31,
		2014		2013
	Accounts receivable	$	13,624,127	$	11,611,741
	Allowance for doubtful accounts		-960,578		-602,243
	Accounts receivable, net	$	12,663,549	$	11,009,498
	The following table presents the movement of the allowance for doubtful accounts:
	Balance, January 1, 2014	$	602,243
	Addition		366,218
	Recovery		—
	Translation adjustment		-7,883
	Balance, March 31, 2014	$	960,578

INVENTORIES

INVENTORIES	3 Months Ended
	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	Note 5 – INVENTORIES
	Inventories consist of the following:
		March 31,		December 31,
		2014		2013
	Raw materials	$	21,970,441		23,001,461
	Packing materials		350,799		396,067
	Work-in-process		152,884		23,140
	Finished goods		2,717,505		2,409,083
	Other		74,154		73,835
	Total	$	25,265,783		25,903,586
	No write-down of inventories was recorded for the three months ended March 31, 2014 and 2013.

DEPOSITS_PREPAID_EXPENSES_AND_

DEPOSITS, PREPAID EXPENSES AND OTHER RECEIVABLES	3 Months Ended
	Mar. 31, 2014
Deposits and Prepaid Expenses Disclosure [Abstract]	'
Deposits and Prepaid Expenses Disclosure [Text Block]	'
	Note 6 - DEPOSITS, PREPAID EXPENSES AND OTHER RECEIVABLES
	Deposits, prepaid expenses and other receivables are comprised of the following:
		March 31,		December 31,
		2014		2013
	Other prepayments	$	365,055	$	478,144
	Deposits placed with guarantors (note 13)		486,900		491,100
	Interest receivable (notes 7 and 12)		168,718		497,844
	Other receivables		587,732		667,075
	Total	$	1,608,405	$	2,134,163

PREPAYMENTS_TO_SUPPLIERS

PREPAYMENTS TO SUPPLIERS	3 Months Ended
	Mar. 31, 2014
Prepayments For Raw Materials Purchasing [Abstract]	'
Prepayments For Raw Materials Purchasing [Text Block]	'
	Note 7 – PREPAYMENTS TO SUPPLIERS
	Prepayments to suppliers are comprised of the following:
		March 31,		December 31,
		2014		2013
	Prepayments for raw materials	$	39,438,992	$	39,937,944
	Prepayments for packaging materials		1,102,483		1,123,200
	Total	$	40,541,475	$	41,061,144
	As part of the Company’s strategy to reduce inventory costs, the Company maintains a balance for prepayments to suppliers in order to secure favorable pricing for raw materials.  As inventory is received throughout the period, this balance will fluctuate with the business operations.
	Starting from January 1, 2013, the Company began to charge two major suppliers interest at an annual rate of 2.0% on the unused prepayments for raw materials. Starting from January 1, 2014, in addition to these two major suppliers, the Company began to charge another supplier interest at an annual rate of 2.0% on the unused prepayments for raw materials. As of March 31, 2014 and December 31, 2013, prepayments to these suppliers were $32,199,192 and $31,953,084, respectively. For the three months ended March 31, 2014 and 2013, $162,205 and $118,182, respectively, of interest income was recognized on these prepayments. The unpaid interest balance of $160,995 and $497,844 as of March 31, 2014 and December 31, 2013, respectively, was included in “Deposits, Prepaid Expenses and Other Receivables” (note 6).

PROPERTY_PLANT_AND_EQUIPMENT_N

PROPERTY, PLANT AND EQUIPMENT, NET	3 Months Ended
	Mar. 31, 2014
Property, Plant and Equipment [Abstract]	'
Property and Equipment, Net [Text Block]	'
	Note 8 - PROPERTY, PLANT AND EQUIPMENT, NET
	Property, plant and equipment consist of the following:
		March 31,		December 31,
		2014		2013
	Buildings and improvements	$	28,033,999	$	27,703,872
	Machinery and equipment		8,261,929		6,093,533
	Office equipment and furniture		334,800		337,688
	Vehicles		606,755		611,989
	Total		37,237,483		34,747,082
	Less: accumulated depreciation		-6,819,830		-6,477,927
	Plant and equipment, net	$	30,417,653	$	28,269,155
	Depreciation expense was $400,291 and $313,561 for the three months ended March 31, 2014 and 2013, respectively.
	As of March 31, 2014 and December 31, 2013, property, plant and equipment with a carrying amount of $3,191,746 and $19,969,335, respectively, were pledged against the Company’s short-term and long-term loans.

CONSTRUCTIONINPROGRESS

CONSTRUCTION-IN-PROGRESS	3 Months Ended
	Mar. 31, 2014
Construction In Progress Disclosure [Abstract]	'
Construction In Progress Disclosure [Text Block]	'
	Note 9 - CONSTRUCTION-IN-PROGRESS
	Construction-in-progress (“CIP”) relates to facilities being built in Xi’an, Jingzhou and Kunshan.
	Xi’an facility
	Xi’an Tianxing has a vaccine facility and animal laboratory being built in Huxian, Xi’an.
	In 2011, the Company started two projects at the vaccine facility to modify air filtration, water treatment, and other facility changes based on recommendations by outside experts hired by the Company to advise on the Good Manufacturing Practices (“GMP”) qualification process for the vaccine facility. In September 2012, the China’s Ministry of Agriculture (“MOA”) physically inspected this facility and deemed the facility GMP compliant. Following physical inspection, the MOA’s inspection team recommended that the Office of the Working Committee proceed with Stage 2 of its GMP certification process.  On December 26, 2013, the MOA granted the GMP certificate for this new facility which is valid for five years, and the facility started to launch trial production in the quarter ended March 31, 2014. Vaccine facility of $2,462,966 was transferred to property, plant and equipment during the three months ended March 31, 2014. The facility is currently in the process of applying for individual product permits from the government. The Company expects to complete the application and launch the normal production in the second half of 2014.
	In 2011, the Company started a facility improvement project in the amount of approximately $324,600 for the Huxian Animal Laboratory. The facility is a supporting project to the Huxian vaccine facility. The project was completed and passed GMP inspection in December 2013. The cost of the animal laboratory of $324,600 was transferred to property, plant and equipment during the three months ended March 31, 2014. The Company expects this facility to become operational once the Huxian vaccine facility launches its manufacturing in the second half of 2014.
	Jingzhou facility
	In 2011, the Company started a facility improvement project to expand the veterinary medicine production capacity at the Jingzhou facility. The project includes plant construction and water supply and drainage and has an estimated total cost of $1,704,150, of which $1,203,130 had been incurred as of March 31, 2014. Due to the revision in the project blueprint to comply with GMP requirements, the project was temporarily halted. The Company expects the project will be resumed in the second quarter of 2014 and be completed by the end of the fourth quarter of 2014.
	Kunshan facility
	In 2011, the Company started a supporting project at the Kunshan micro-organism facility that includes the construction and installation of plumbing, sewer, electrical, HVAC, fire protection and alarm system, drainage, office, lab, road construction, parking, and landscaping. As of December 31, 2013, the construction and installation of these facilities were completed, inspected and accepted. However, the construction-in-progress of $5,267,642 has not been transferred to property, plant and equipment as the Kunshan micro-organism facility was not operational at this point. During the third quarter of 2013, the Company contracted with an unrelated third party to purchase machinery and equipment at a total consideration of approximately $7,303,500, of which $3,482,958 was paid and was included in “Long-term prepayments” (note 10) as of March 31, 2014. The Company expects the purchase and installation of this equipment will be completed by the end of the third quarter of 2014.
	No depreciation is provided for construction-in-progress until such time as the assets are completed and placed into service.
	The construction projects the Company was in the progress of completing are as follows:
		Total in CIP
		as of
	Project	March 31,		Estimated Cost to		Estimated		Estimated
		2014		Complete		Total Cost		Completion Date
	Jingzhou veterinary medication facility	$	1,203,130	$	501,020	$	1,704,150	Fourth quarter of 2014
	Kunshan micro-organism facility		5,267,642		7,241,039		12,508,681	Construction - completed, Installation of machinery and equipment – Third quarter of 2014
	Total	$	6,470,772	$	7,742,059	$	14,212,831
	As of March 31, 2014 and December 31, 2013, the Company had construction in progress amounting to $6,470,772 and $9,284,947, respectively. Interest expense of $53,195 and $nil has been capitalized for construction in progress for the three months ended March 31, 2014 and 2013, respectively.

LONGTERM_PREPAYMENTS

LONG-TERM PREPAYMENTS	3 Months Ended
	Mar. 31, 2014
Long Term Prepayments Disclosure [Abstract]	'
Long Term Prepayments Disclosure [Text Block]	'
	Note 10 - LONG-TERM PREPAYMENTS
	Long-term prepayments consist of the following:
		March 31,		December 31,
		2014		2013
	Deposits for equipment purchase and land use rights	$	3,836,884	$	3,871,228
	Construction deposits		386,224		366,688
	Prepayments for R&D project		363,552		389,556
	Deposits for other		6,091		6,142
	Long-term prepayments	$	4,592,751	$	4,633,614
	Long-term prepayments for acquisitions	$	-	$	183,344
	As of March 31, 2014 and December 31, 2013, deposits for potential acquisitions totaled $Nil and $183,344, respectively, all of which was held by an unrelated third party engaged to facilitate potential acquisition projects.

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	Note 11 – INTANGIBLE ASSETS
	Intangible assets consist of the following:
		March 31,		December 31,
		2014		2013
	Land use rights	$	4,909,577	$	4,951,927
	Technological know-how		2,596,800		2,619,200
	Total		7,506,377		7,571,127
	Less: accumulated amortization		-2,375,923		-2,333,872
	Intangible assets, net	$	5,130,454	$	5,237,255
	For the three months ended March 31, 2014 and 2013, the amortization expense for intangibles amounted to $62,477 and $60,872, respectively.
	Amortization expense expected for the next five years and thereafter is as follows:
	Years ending December 31,	Amount
	2014	$	186,032
	2015		248,042
	2016		248,042
	2017		248,042
	2018		248,042
	Thereafter		3,952,254
	Total	$	5,130,454
	As of March 31, 2014 and December 31, 2013, land use rights with a carrying amount of $1,136,461 and $1,529,960, respectively, were pledged against the Company’s short-term loans.

LOANS_RECEIVABLE

LOANS RECEIVABLE	3 Months Ended
	Mar. 31, 2014
Receivables [Abstract]	'
Loans Receivable Disclosure [Text Block]	'
	Note 12 – LOANS RECEIVABLE
	On January 2, 2014, the Company entered a loan agreement with Shaanxi Feilong Logistics Co., Ltd., (“Feilong”), the Company’s major logistics provider, to lend up to $1,298,400 (RMB 8,000,000) to Feilong. This loan agreement expires on May 31, 2014 with an annual interest rate of 6%. During the three months ended March 31, 2014, Feilong borrowed a total amount of $1,046,835 (RMB 6,450,000) from the Company.  Interest income earned on this unsecured loan amounted to $7,781 for the three months ended March 31, 2014. The unpaid interest balance of $7,723 as of March 31, 2014 was included in “Deposits, Prepaid Expenses and Other Receivables” (note 6).

SHORTTERM_LOANS

SHORT-TERM LOANS	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Short-term Debt [Text Block]	'
	Note 13 – SHORT-TERM LOANS
	On January 16, 2013, the Company obtained a one year loan with Industrial Bank Co. Ltd. Xi’an branch for $4,869,000 (RMB 30,000,000) at an annual interest rate of 6.6%. This loan was secured by the Company’s land use rights and manufacturing plant located in Huxian County. This loan was also personally guaranteed by the Company’s Chairman and CEO and his wife. On January 15, 2014, the loan was fully repaid.
	On April 16, 2013, the Company obtained a one year loan from May 27, 2013 to May 26, 2014 with Postal Savings Bank of China Xi’an Branch for $3,246,000 (RMB 20,000,000) at an annual interest rate determined by using the People's Bank of China floating benchmark lending rate over the same period plus 20% of that rate, which was 7.2% at March 31, 2014. This loan is guaranteed by Xi’an Investment and Financing Guarantee Co., Ltd. For this guarantee, the Company is required to pay $58,158 (RMB 360,000) of fees to Xi’an Investment and Financing Guarantee Co., Ltd. and 10% of the loan or $324,600 (RMB 2,000,000) is required to be kept by Xi’an Investment and Financing Guarantee Co., Ltd. to serve as collateral until the loan is repaid. This loan is secured by the Company’s office buildings located in Xi’an, Shaanxi Province and the manufacturing equipment in Huxian County. The Company’s Chairman and CEO, his wife, and two other company’s managers have provided personal guarantees to Xi’an Investment and Financing Guarantee Co., Ltd. for the repayment of the loan.
	On June 13, 2013, the Company obtained a one year loan from June 20, 2013 to June 19, 2014 with Industrial and Commercial Bank of China (ICBC) Songzi Branch for $811,500 (RMB 5,000,000) at an annual interest rate determined by using the People's Bank of China floating benchmark lending rate over the same period plus 30% of that rate, which was 7.8% at March 31, 2014. The Company is originally required to keep 10% of the loan or $81,150 (RMB 500,000) with the bank as collateral. During the fourth quarter of 2013, the collateral was waived. This loan is secured by the Company’s buildings and land use rights in Jingzhou, Hubei Province.
	On September 10, 2013, the Company entered into a loan agreement with its Chairman and CEO. Under the agreement, the Chairman and CEO obtained a one year personal bank loan from September 12, 2013 to September 11, 2014 with Bank of Beijing of $1,623,000 (RMB 10,000,000) and lent the entire loan proceeds to the Company. The interest and repayment terms of the loan from the Chairman and CEO are identical to those of the personal bank loan. The annual interest rate is determined by using the prime rate over the same period plus 30% of that rate, which was 7.8% at the date that the loan was issued. The Company agrees to bear all the costs and expenses associated with the personal bank loan. The personal bank loan is guaranteed by Xi’an Investment and Financing Guarantee Co., Ltd. For this guarantee, the CEO is required to (i) pay $29,434 (RMB 180,000) of fees to Xi’an Investment and Financing Guarantee Co., Ltd. This cost has been paid and recorded as an expense of the Company using the effective interest method for the three months ended March 31, 2014; and (ii) place 10% of the loan or $162,300 (RMB 1,000,000) at Xi’an Investment and Financing Guarantee Co., Ltd. to serve as collateral until the loan is repaid. The Company had placed such a deposit with Xi’an Investment and Financing Guarantee Co., Ltd. as of March 31, 2014. The personal bank loan is also secured by the Chairman and CEO’s real estate properties and the Company’s office buildings and machineries located in Xi’an.
	On April 14, 2014, the Company entered into a six-month Banker’s Acceptance agreement with Chang’an Bank for $7,790,400 (RMB 48,000,000) at a six-month interest rate of 3%. The Banker’s Acceptance was issued on April 21, 2014 and secured by pledged deposits placed with Chang’an Bank of $3,895,200 (RMB 24,000,000), and the Company’s land use rights and manufacturing plant located in Huxian County with a carrying value of $16,811,260 as of March 31, 2014. This Banker’s Acceptance was also personally guaranteed by the Company’s Chairman and CEO and his wife. The fee to cash the Banker’s Acceptance is 0.05% of the face value of this Banker’s Acceptance or $3,895 (RMB 24,000). Pursuant to this Bank’s Acceptance, loans of $7,790,400 (RMB 48,000,000) were drawn down as of April 21, 2014.
	Outstanding short-term loans consisted of the following:
			March 31, 2014				December 31, 2013					Interest
	Bank		Amt RMB		Amt USD		Amt RMB		Amt USD		Due Date	Rate
	Industrial Bank Co. Ltd. Xi’an Branch			-	$	-		30,000,000	$	4,911,000	1/15/14		6.6	%
	Postal Savings Bank of China Xi’an Branch			20,000,000		3,246,000		20,000,000		3,274,000	5/26/14		-2
	ICBC Songzi Branch			5,000,000		811,500		5,000,000		818,500	6/19/14		-1
	Related-party Individual – Chairman and CEO			10,000,000		1,623,000		10,000,000		1,637,000	9/11/14		7.8	%
	Total			35,000,000	$	5,680,500		65,000,000	$	10,640,500
		-1	People's Bank of China floating benchmark lending rate over the same period plus 30%, which was 7.8% at March 31, 2014.
		-2	People's Bank of China floating benchmark lending rate over the same period plus 20%, which was 7.2% at March 31, 2014.
	Interest expense incurred and associated with the short-term loans amounted to $129,129 and $189,392 for the three months ended March 31, 2014 and 2013, respectively, $53,195 and $nil of which has been capitalized as part of construction-in-progress in 2014 and 2013, respectively.

DEFERRED_GOVERNMENT_GRANT

DEFERRED GOVERNMENT GRANT	3 Months Ended
	Mar. 31, 2014
Deferred Government Grant Disclosure [Abstract]	'
Deferred Government Grant Disclosure [Text Block]	'
	Note 14 - DEFERRED GOVERNMENT GRANT
	The subsidies for Good Manufacturing Practice projects were granted by Shaanxi provincial government and Xi’an municipal government which may require the subsidies to be repaid. As of March 31, 2014 and December 31, 2013, the subsidies were RMB 2,500,000, equivalent to $405,750 and $409,250, respectively.
	The subsidies granted by Xi’an City Science and Technology Bureau and Xi’an City High-Tech Industrial Development Zone are required to be used exclusively for the fish disease multi associated anti-idiotypic monoclonal antibody vaccine project during the development period from January 2012 through December 2014. As of March 31, 2014 and December 31, 2013, 70% of the subsidies or RMB 4,200,000, equivalent to $681,660 and $687,540, respectively had been received and RMB 3,000,000 equivalent to $486,900 and $491,100 has been expensed on this project and were accounted for as an offset against deferred government grant as of March 31, 2014 and December 31, 2013, respectively.
	The interest subsidies granted by Xi’an municipal government were required to be used exclusively for the chicken coccidia vaccine project in the third quarter of 2013. As of March 31, 2014 and December 31, 2013, the subsidies of RMB 1,200,000, equivalent to $194,760 and $196,440 had been received and nil has been expensed on this project.

CAPITAL_TRANSACTIONS

CAPITAL TRANSACTIONS	3 Months Ended
	Mar. 31, 2014
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	Note 15 - CAPITAL TRANSACTIONS
	Stock-based compensation
	On March 31, 2012, the Company entered into an agreement with a non-executive director to grant him an aggregate 28,000 shares of restricted common stock each year under the Company’s 2010 Stock Incentive Plan, vested in four equal quarterly installments of 7,000 shares. The closing price per share of the stock on the next business day of each of the grant date in 2012 and 2013 was $2.95 and $1.73 respectively. The Board of Directors approved his agreement with the Company on March 10, 2014. As of March 31, 2014 and December 31, 2013, 56,000 shares and 49,000 shares, respectively, were vested and to be issued to this non-executive director.
	On May 26, 2009, the Company agreed to issue 5,556 shares of common stock to a director at the beginning of each term of his directorship, which runs from May 26, 2013 to May 25, 2014. In accordance with the agreement between the Company and this director, this director must continue to serve as a member of the Board until his successor is duly elected and qualified in order to receive the shares. The closing price per share of the stock on the next business day of each of the grant date in 2012 and 2013 was $2.39 and $1.20 respectively. As of March 31, 2014 and December 31, 2013, 11,112 shares were vested and to be issued to this non-executive director.
	On July 29, 2011, the Company entered into a one-year employment agreement with its CFO effective July 29, 2011. Under the agreement, he is entitled to receive an aggregate 8,000 shares of common stock, 4,000 shares of which shall be issuable on the 6 month anniversary and the remaining 4,000 shares of which shall be issuable on the 12 month anniversary. The closing price per share on the grant date was $4.20. On July 29, 2012, the Company entered into another one-year employment agreement with the CFO effective July 29, 2012. Under the agreement, he is entitled to receive an aggregate 8,000 shares of common stock, vested in four equal quarterly installments of 2,000 shares. The closing price per share of the stock on the next business day of the grant date was $2.17. On July 29, 2013, the Company entered into another one-year employment agreement with the CFO effective July 29, 2013. Under the agreement, he is entitled to receive an aggregate 8,000 shares of common stock, vested in four equal quarterly installments of 2,000 shares. The closing price per share of the stock on the next business day of the grant date in 2013 and 2012 was $1.37 and $2.17 respectively. The Board of Directors ratified and approved the CFO’s employment agreement with the Company on March 10, 2014. As of March 31, 2014 and December 31, 2013, 12,000 shares and 10,000 shares were vested and to be issued to this executive, respectively.
	The Company entered into a five-year employment agreement with its Chief Executive Officer on May 5, 2008. After the agreement was expired on December 31, 2013, the Company renewed the employment agreement with its Chief Executive Officer for another five year period effective January 1, 2014. Under the agreement, he is entitled to receive an aggregate 50,000 shares of common stock , vested in four equal quarterly installments of 12,500 shares. The closing price per share of the stock on the next business day of each of the grant date in 2014 was $3.59. The Board of Directors ratified and approved the CEO’s employment agreement with the Company on March 10, 2014. As of March 31, 2014, 12,500 shares were vested and to be issued to this executive.
	The Company recorded $59,725 and $4,340 share based compensation for the three months ended March 31, 2014 and 2013, respectively.
	Equity Compensation Plan
	On December 8, 2009, the Company’s board of directors approved a stock incentive plan for officers, directors, employees and consultants entitled the “Skystar Bio-Pharmaceutical Company 2010 Stock Incentive Plan” (the “2010 Plan”). The maximum number of shares that may be issued under the 2010 Plan is 700,000 shares of common stock. The 2010 Plan was approved by the Company’s stockholders on December 31, 2009, and awards may be granted thereunder until December 7, 2019. On May 4, 2012, the Board approved common stock grants in the total amount of 442,881 shares to the Company’s employees and members of the Board of Directors, all of which grants were made pursuant to the terms and provisions of the Plan. As of March 31, 2014 and December 31, 2013, there are 247,119 shares of the Company’s common stock remaining available for future issuance under the Plan. As of March 31, 2014 and December 31, 2013, there are 91,612 shares and 70,112 shares, respectively, vested pending to be issued.
	A summary of changes in the Company’s non-vested shares for the year follows:
		Non-vested Shares
	Non-vested at January 1, 2013		6,000
	Granted		69,556
	Vested		-62,556
	Forfeited		-
	Non-vested at December 31, 2013		13,000
	Granted		50,000
	Vested		-21,500
	Forfeited		-
	Non-vested at March 31, 2014		41,500
	As of March 31, 2014, there was $138,198 of total unrecognized compensation cost related to non-vested shares granted.  The total fair value of shares vested during the three months ended March 31, 2014 and 2013 was $59,725 and $4,340, respectively, based on the closing price of the Company’s common stock on the next business day of the grant date.
	Purchase Options
	In connection with the 2009 equity offering, the Company granted 140,000 common stock purchase options to five designees of the Underwriters with a vesting date of June 30, 2010. The options are exercisable from June 30, 2010 to June 30, 2014, and each option is exercisable for one share of the Company’s common stock at an exercise price at $8.11 per share. All options were provided for services performed. As of March 31, 2014 and December 31, 2013, 140,000 common stock purchase options remained outstanding.
	Outstanding purchase options do not trade in an active securities market, and as such, the Company estimates the fair value of these purchase options using the Black-Scholes Option Pricing Model (“Black-Scholes Model”) using the following assumptions:
		Purchase Options
		March 31,				December 31,
		2014				2013
	Stock price	$	6.56			$	3.51
	Exercise price	$	8.11			$	8.11
	Annual dividend yield		-				-
	Expected term (years)		0.25				0.5
	Risk-free interest rate		0.05	%			0.1	%
	Expected volatility		80	%			125	%
	Option value	$	0.56			$	0.45
	Expected volatility is based on historical volatility. Historical volatility was computed using daily pricing observations for recent periods that correspond to the term of the warrants. The Company believes this method produces an estimate that is representative of future volatility over the expected term of these warrants and purchase options. The Company has no reason to believe future volatility over the expected remaining life of these purchase options is likely to differ materially from historical volatility. The expected life is based on the remaining term of the purchase options. The risk-free interest rate is based on U.S. Treasury securities according to the remaining term of the purchase options.
	As required by the FASB’s accounting standards, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Depending on the nature and the terms of the transaction, the fair values of the warrant/purchase option liability were modeled using a series of techniques, including closed-form analytic formula, such as the Black-Scholes Model, which does not entail material subjectivity because the methodology employed does not necessitate significant judgment, and the pricing inputs are observed from actively quoted markets.
	The fair value of the 140,000 purchase options outstanding as of March 31, 2014 and December 31, 2013 was determined using the Black-Scholes Model, utilizing level 2 inputs, and the change was recorded in earnings. The Company recognized a loss of $16,520 and a gain of $4,466 from the change in fair value of derivative liability for the three months ended March 31, 2014 and 2013, respectively.
	Following is an activity summary of the Company’s outstanding purchase options:
		Number of			Weighted –			Weighted-
		purchase			average			average
		options			exercise price			remaining
								contractual term
								(Year)
	Outstanding at January 1, 2014		140,000		$	8.11			0.5
	Granted		-			-
	Forfeited		-			-
	Exercised		-			-
	Outstanding at March 31, 2014		140,000		$	8.11			0.25
	Exercisable at March 31, 2014		140,000		$	8.11			0.25

STATUTORY_RESERVES

STATUTORY RESERVES	3 Months Ended
	Mar. 31, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	Note 16 - STATUTORY RESERVES
	Statutory reserves represent restricted retained earnings. Based on the legal formation of the entities, all PRC entities are required to set aside 10% of net income as reported in their statutory accounts on an annual basis to the statutory surplus reserve fund. Once the total statutory surplus reserve reaches 50% of the entity’s registered capital, further appropriations are discretionary. The statutory surplus reserve can be used to increase the entity’s registered capital (upon approval by relevant government authorities) and eliminate its future losses under PRC regulatory requirements (upon a resolution by the board of directors). The statutory surplus reserve is not distributable to shareholders except in the event of liquidation.
	Appropriations to the above statutory reserves are accounted for as a transfer from unrestricted earnings to statutory reserves. There are no legal requirements in the PRC to fund these statutory reserves by the transfer of cash to any restricted accounts, and as such, the Company has not transferred any cash to these accounts. These reserves are not distributable as cash dividends.

TAXES

TAXES	3 Months Ended
	Mar. 31, 2014
Taxes Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	Note 17 – TAXES
	Provision for income taxes consisted of the following:
			Three months ended March 31,
	PRC income taxes		2014			2013
	Current		$	472,407		$	321,284
	Deferred			-42,380			-
	Total		$	430,027		$	321,284
	Skystar is subject to United States federal income tax. Skystar Cayman is a tax-exempt company incorporated in the Cayman Islands. Fortune Time did not have any assessable profits arising in or derived from Hong Kong for the three months ended March 31, 2014 and 2013, and accordingly no provision for Hong Kong profits tax was made in these periods.
	The Company’s subsidiaries and VIEs are subject to the PRC’s Enterprise Income Tax. Pursuant to the PRC Income Tax Laws, Enterprise Income Tax is generally imposed at a statutory rate of 25%. Xi’an Tianxing has been approved as a new technology enterprise, and under PRC Income Tax Laws is entitled to a preferential tax rate of 15%.
	The following table reconciles the U.S. statutory rates to the Company’s effective tax rate for the three months ended March 31, 2014 and 2013:
			Three Months ended March 31,
			2014			2013
	U.S. statutory rate		34	%		34	%
	Foreign income not recognized in the U.S.		-34			-34
	China income tax rate		25			25
	China income tax exemption		-10			-10
	Other items (1)		15.6			16.1
	Total provision for income taxes		30.6	%		31.1	%
		-1	Other items are primarily for operating expenses (income) incurred by Skystar that are not deductible (taxable) in the PRC, expenses incurred by other subsidiaries that are not deductible on the consolidated level, the difference of taxable income under US GAAP rather than Chinese GAAP, and the difference of Enterprise Income Tax imposed at a statutory rate of 25% rather than preferential tax rate of 15% on the income from the subsidiaries other than Xi’an Tianxing, which resulted in an increase in the effective tax rate of 15.6% and 16.1% for the three months ended March 31, 2014 and 2013, respectively.
			Other items consisted of the following:
			Three Months ended March 31,
			2014		2013
	Income taxed at Chinese statutory rate of 25%		1.3	%	1	%
	Valuation allowance on tax loss		8.3		9.9
	Share based compensation		0.6		0.1
	Non-deductible operating expenses		5.4		5.1
	Total other items		15.6	%	16.1	%
	Taxes payable consisted of the following:
			March 31,			December 31,
			2014			2013
	Income taxes		$	1,126,025		$	662,811
	Value added taxes			1,526,475			576,603
	Other taxes			200,344			76,072
	Total		$	2,852,844		$	1,315,486
	As of March 31, 2014 and December 31, 2013, the estimated net operating loss carry forwards of Skystar for U.S. income tax purposes amounted to $5,069,380 and $4,917,108, which may be available to reduce future years’ taxable income. These carry forwards will expire, if not utilized, beginning in 2025 and through 2033. As of March 31, 2014 and December 31, 2013, the estimated net operating loss carry forwards of Skystar for PRC income tax purposes amounted to $5,039,534 and $4,572,233, which may be available to reduce future years’ taxable income. These carry forwards will expire, if not utilized, through 2018. Management believes that the realization of the arising from this loss appears to be uncertain due to the Company’s limited operating history and continuing losses for U.S. and PRC income tax purposes. Accordingly, the Company has provided a 100% valuation allowance at March 31, 2014 and December 31, 2013. As of March 31, 2014 and December 31, 2013, the valuation allowance on the tax loss of Skystar was $1,723,589 and $1,671,817, respectively, and that of PRC subsidiaries was $1,259,883 and $1,142,813, respectively. The Company’s management reviews this valuation allowance periodically and makes adjustments as necessary. As of March 31, 2014, the Company had deferred tax assets amounting to $403,372, in respect of accrued expenses of $163,227 and an allowance on doubtful accounts of $240,145. As of December 31, 2013, the Company had deferred tax assets amounting to $364,425, in respect of accrued expenses of $213,865 and an allowance on doubtful accounts of $150,560.
	The Company did not provide for deferred income taxes and foreign withholding taxes on the cumulative undistributed earnings of foreign subsidiaries as of March 31, 2014 and December 31, 2013 of approximately $52.9 million and $50.9 million, respectively. The cumulative undistributed earnings of foreign subsidiaries were included in consolidated retained earnings and will continue to be indefinitely reinvested in international operations.  Accordingly, no provision has been made for U.S. deferred taxes or applicable withholding taxes, related to future repatriation of these earnings, nor is it practicable to estimate the amount of income taxes that would have to be provided if management concluded that such earnings will be remitted in the future.

EARNINGS_PER_SHARE

EARNINGS PER SHARE	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	Note 18 - EARNINGS PER SHARE
	The following is the calculation of earnings per share:
		Three months ended March 31,
		2014		2013
	Net income	$	975,450	$	712,733
	Weighted average shares used in basic computation		7,676,268		7,613,712
	Effect of dilutive potential non-vested common shares		24,466		-
	Weighted average shares used in diluted computation		7,700,734		7,613,712
	Earnings per share:
	Basic	$	0.13	$	0.09
	Diluted	$	0.13	$	0.09
	For the three months ended March 31, 2014, the outstanding 140,000 options were excluded from the diluted earnings per share calculation as they are anti-dilutive as the average stock price was less than the exercise prices of the options.
	For the three months ended March 31, 2013, the outstanding 140,000 options and 4,000 non-vested shares were excluded from the diluted earnings per share calculation as they are anti-dilutive.

RELATED_PARTY_TRANSACTIONS_AND

RELATED PARTY TRANSACTIONS AND ARRANGEMENTS	3 Months Ended
	Mar. 31, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	Note 19 - RELATED PARTY TRANSACTIONS AND ARRANGEMENTS
	Amounts payable to related parties are summarized as follows:
			March 31,		December 31,
			2014		2013
	Amounts due to related parties
	Weibing Lu – CEO (1)		$	1,155,155	$	857,012
	Bing Mei – CFO (3)			92,209		41,283
	Scott Cramer – non-executive director and shareholder (2)			530,349		300,203
	Directors, shareholders and other related parties (4)			184,525		163,050
	Total		$	1,962,238	$	1,361,548
		-1	As of March 31, 2014 and December 31, 2013, the Company had unpaid reimbursement, compensation, and advances for business expenses due to Weibing Lu valued at $1,155,155 and $857,012, respectively.
		-2	As of March 31, 2014 and December 31, 2013, the Company had unpaid reimbursement and compensation due to Scott Cramer valued at $530,349 and $300,203, respectively. On March 10, 2014, the Board of Directors, including all of the independent members of the Board, reviewed and approved the terms of Mr. Cramer’s Consulting Services Agreement with the Company pursuant to which the Company would continue employing him as its US representative in consideration of (i) a quarterly cash fee of $7,500, (ii) 7,000 restricted shares of the Company’s common stock issuable on a quarterly basis pursuant to the Company’s 2010 Stock Incentive Plan (note 15), and (iii) reimbursement of out of pocket expenses.  In addition, Mr. Cramer agreed to pay certain invoices of the Company to its vendors (and the Company agreed to reimburse Mr. Cramer) in the form of a no interest bearing loan in the aggregate amount of approximately $250,000.
		-3	As of March 31, 2014 and December 31, 2013, the Company had unpaid reimbursement and compensation due to Bing Mei valued at $92,209 and $41,283, respectively.
		-4	The amounts due to directors, shareholders and other related parties at March 31, 2014 and December 31, 2013 include unpaid reimbursement and advances to other related parties for business expenses.
	Also refer to Notes 13, 15 and 20 for other related party transactions and arrangements.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	Note 20 - COMMITMENTS AND CONTINGENCIES
	(a)  Lease commitments
	The Company recognizes lease expense on the straight-line basis over the term of the lease.
	The Company entered into a tenancy agreement for the lease of factory premises of Xi’an Tianxing in Sanqiao for a period of ten years from October 1, 2004 to December 31, 2014. The annual rent for the factory premises is subject to a 10% increase every two years starting October 1, 2009. As of March 31, 2014, the annual rent for the factory premises was approximately $22,780 (RMB 140,360).
	The Company leased office space in Xi’an from Mr. Weibing Lu, the Company’s Chairman and CEO, for a period of five years from January 1, 2007 to December 31, 2011. In January 2012, the Company renewed the lease with Mr. Lu for another 5 years from January 1, 2012 to December 31, 2016 at a rent of approximately $29,214 (RMB 180,000) per year.
	The Company also entered into a tenancy agreement with Mr. Weibing Lu for the lease of Shanghai Siqiang’s office in Shanghai for a period of ten years from August 1, 2007 to August 1, 2017 with an annual rent of approximately $23,371 (RMB 144,000).
	The Company entered into a one year tenancy agreement for an office lease in Kunshan, Jiangsu Province from October 15, 2012 to April 14, 2013 with a six-month rent of approximately $1,689 (RMB 10,405). On April 15, 2013, the Company entered into an another one-year tenancy agreement for this office from April 15, 2013 to April 14, 2014 with a one-year rent of approximately $3,820 (RMB 23,536). On April 17, 2014, the Company entered into an another one-year tenancy agreement for this office from April 15, 2014 to April 14, 2015 with a one-year rent of approximately $3,820 (RMB 23,536).
	The Company entered into a tenancy agreement for the lease of warehouse premises in Xi’an for a period of three years from July 20, 2011 to July 19, 2014 with an annual rent of approximately $38,141 (RMB 235,000) subject to a 10% increase every two years starting July 20, 2013. As of March 31, 2014, the annual rent for the warehouse premises was approximately $41,955 (RMB 258,500).
	The Company entered into a tenancy agreement for the lease of a sales office in Jingzhou, Hubei Province for a period of five years from April 18, 2012 to April 17, 2017 with an annual rent of approximately $8,764 (RMB 54,000) for the first three years subject to increase during last two years.
	The minimum future lease payments for the next five years and thereafter are as follows:
	Period	Unrelated third		Related parties		Total
		parties
	Year ending December 31, 2014	$	25,761	$	46,742	$	72,503
	Year ending December 31, 2015		8,764		52,585		61,349
	Year ending December 31, 2016		8,764		52,585		61,349
	Year ending December 31, 2017 and thereafter		2,191		13,633		15,824
	Total	$	45,480	$	165,545	$	211,025
	Rental expense to unrelated third parties for the three months ended March 31, 2014 and 2013 amounted to $18,921 and $15,271, respectively. Rental expense to related parties for the three months ended March 31, 2014 and 2013 amounted to $13,245 and $12,905, respectively.
	(b)  Legal proceedings
	From time to time, the Company is involved in legal matters arising in the ordinary course of business. Management currently is not aware of any legal matters or pending litigation that would have a significant effect on the Company’s condensed consolidated financial statements as of March 31, 2014.
	In May 2007, Andrew Chien filed suit against the Company, R. Scott Cramer, Steve Lowe, David Wassung and Weibing Lu in United States District Court for the District of Connecticut, alleging causes of action for violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On July 17, 2008, in a decision that is now published, the court granted defendants’ motion to dismiss and subsequently dismissed the lawsuit, entering judgment on behalf of the defendants. Chien appealed the dismissal. Defendants filed a post judgment motion for sanctions against Chien. On February 5, 2009, the court found the action filed by Chien to have been frivolous, and to have constituted a “substantial” violation of Rule 11, and imposed monetary sanctions on both Chien and his former attorney. Chien appealed the award of sanctions. All appeals, including the one referenced below concerning Chien’s second lawsuit, were subsequently consolidated. The Court of Appeals issued a Mandate upholding the decision granting defendant’s motion to dismiss and found that the District Court did not “abuse its discretion” in issuing sanctions against Chien in light of the circumstances and facts on record. This Mandate was entered on or about November 8, 2010.
	Andrew Chien, proceeding pro se (i.e., he represented himself without an attorney), filed his second lawsuit against the Company, R. Scott Cramer, Steve Lowe, David Wassung and Weibing Lu in Connecticut Superior Court (which was removed to U.S. District Court) alleging causes of action similar to those alleged in his federal complaint described above as well as state law causes of action. The court held that all claims asserted against the defendants were barred and failed to state a claim on a multiplicity of grounds, including on the basis of res judicata. Defendants filed a second Motion for Sanctions under Rule 11 and the PSLRA, which was granted. Chien appealed the dismissal. The Court of Appeals for the Second Circuit consolidated all of Chien’s appeals from both of his lawsuits. On November 8, 2010, the Court of Appeals affirmed the dismissals and the awards of sanctions. On January 22, 2011, Chien filed a petition with the Supreme Court of the United States, appealing the lower court’s ruling. The Supreme Court denied review of the petition.
	Andrew Chien, again proceeding pro se, commenced his third lawsuit against the Company, Scott Cramer, Steve Lowe, David Wassung, Weibing Lu (and also Weinberg & Company, P.A., Moore Stephens Wirth Frazer & Torbet, LLP, Frazer Frost, LLP, Crowe Horwath LLP, Richardson & Patel LLP, Kevin K. Leung, Harvey Kesner, and Jody M. Borrelli) alleging the same facts and circumstances as set forth in the above two matters, although adding the aforementioned accountants and lawyers as defendants to the claims. The matter commenced on August 8, 2011, and shortly thereafter was removed to U.S. District Court. On October 5, 2011, the court dismissed the entire action as to all defendants. As in the two previous lawsuits, sanctions were issued against Chien. Moreover, the District Court issued an order prohibiting Chien from filing any more lawsuits against the defedentants without prior approval from the court. Chien appealed the Court’s ruling to the United States Court of Appeals for the Second Circuit, where all defendants have filed motions to dismiss.
	The United States Court of Appeals for the Second Circuit recently affirmed the judgments and orders of the United States District Court and dismissed all of Mr. Chien’s pending appeals.
	Although the Second Circuit declined to issue sanctions against Chien, it expressly warned Chien “that the continued filing of duplicative, vexatious, or frivolous appeals regarding issues already resolved by this Court may result in the imposition of sanctions, including a leave-to-file sanction requiring Chien to obtain permission from this Court prior to filing further submissions in this Court.” The Supreme Court of the United States denied Chien’s petition for writs of certiorari.
	(c) R&D project
	In 2008, Xi’an Tianxing contracted with Northwestern Agricultural Technology University to work jointly on an R&D project concerning the application of nano-technology in the prevention of major milk cow disease. The total projected budget for this project is approximately $649,200 (RMB 4,000,000), which is to be paid according to completed stages of the project. The project reached trial stage in September 2009. As of March 31, 2014, the Company has incurred approximately $568,050 (RMB 3,500,000) of cumulative expenses relating to this project.
	In 2009, Xi’an Tianxing contracted with the Fourth Military Medical University to jointly work on an R&D project on fish diseases linked immunosorbent detection kit and fish diseases multi-linked monoclonal antibody therapeutic agents. The contracted amount for this project is approximated $973,800 (RMB 6,000,000). As of March 31, 2014, the Company has incurred approximately $843,960 (RMB 5,200,000) of cumulative expenses relating to this project.
	During the first quarter of 2011, Xi’an Tianxing contracted with the Fourth Military Medical University to jointly work on an R&D project to develop new treatment and diagnosis method for Mycoplasmal pneumonia of swine. The project term is from January 2011 through September 2013. The cost to the Company for the initial phase is approximately $324,600 (RMB 2,000,000). As of March 31, 2014, the project was extended for clinical trials and the Company has incurred approximately $243,450 (RMB 1,500,000). The project is expected to be completed by the end of 2015.
	During the fourth quarter of 2012, Xi’an Tianxing launched eight in-house R&D projects as set forth in the following table. As of March 31, 2014, the Company incurred all the budget expenses and these projects were still under development.
	During the second quarter of 2013, Xi’an Tianxing launched an R&D project to develop monoclonal antibody vaccine to prevent common fish skin disease. The cost to the Company for this project is approximately $568,050 (RMB 3,500,000). As of March 31, 2014, the Company has incurred $486,900 (RMB 3,000,000) and this project is still under development.
	During the third quarter of 2013, Xi’an Tianxing launched an R&D project to develop livestock and avian disease multi-joint yolk antibody therapeutic agents and contracted with Lantian County Chicken Farm to test the effect of its developed agents. The project is expected to be completed by the end of 2014. The total projected budget for this project is approximately $714,120 (RMB 4,400,000). As of March 31, 2014, the Company has incurred $324,600 (RMB 2,000,000) and this project is still under development.
	In addition, the Company also launched various R&D projects on veterinary products formula adjustment, pet drug development, fermentation engineering design and development, GMP inspection trial production tests and lab tests. As of March 31, 2014, $1,665,948 (RMB 10,264,620) has been incurred related to these projects and lab tests.
	R&D projects are summarized as follows:
	Project	Amount		Amount		Total amount
		incurred as		expected to be		of
		of 03/31/2014		incurred		project
	Project with Northwestern Agricultural Technology University
	Application of nano-technology in the prevention of major milk cow disease	$	568,050	$	81,150	$	649,200
	Project with the Fourth Military Medical University
	Fish diseases linked immunosorbent detection kit and fish diseases Multi-linked monoclonal antibody therapeutic agents		843,960		129,840		973,800
	New treatment and diagnosis method for Mycoplasmal pneumonia of swine		243,450		81,150		324,600
	In-house R&D projects during 2012:
	Oral liquid products R&D and field trials		162,300		-		162,300
	Powder for injection products R&D and field trials		162,300		-		162,300
	Vitamin E injection product development		81,150		-		81,150
	Anthelmintic product development		81,150		-		81,150
	Three disease grams product development		81,150		-		81,150
	Premixes class product development		81,150		-		81,150
	Bulk powder products development		81,150		-		81,150
	Livestock and fish diseases immunoassay kit development		405,750		-		405,750
	In-house R&D projects during 2013:
	Fish monoclonal antibody vaccine		486,900		81,150		568,050
	Livestock and avian disease multi-joint yolk antibody therapeutic agents		324,600		389,520		714,120
	Other projects for veterinary products formula adjustment, pet drug development, fermentation engineering design and development, GMP inspection trial production tests and other lab tests		1,665,948		16,230		1,682,178
	Total	$	5,269,008	$	779,040	$	6,048,048
	All payments made for R&D projects have been expensed as incurred.
	(d) Registered capital commitment:
	Skystar Kunshan’s remaining registered capital of $12,750,000 was originally required to be invested by May 7, 2012. On March 26, 2014, the Company received the approval of extension for payment of the remaining registered capital to May 6, 2015.
	(e) Capital commitment
	The Company’s commitments for capital expenditure as of March 31, 2014 are as follows:
	Contracted but not accrued for:
	Purchase of machinery and construction (Note 9)	$	4,321,562

SEGEMENT_INFORMATION

SEGEMENT INFORMATION	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	Note 21 – SEGEMENT INFORMATION
	The Company currently engages in one business segment, the research, development, production, marketing and sales of veterinary healthcare and medical care products. The Company’s revenues and cost of revenues by product line were as follows:
		Three Months Ended
		March 31,
		2014		2013
	Revenues
	Micro-organism	$	1,521,165	$	1,667,182
	Veterinary Medications		4,844,968		3,446,717
	Feed Additives		330,537		286,288
	Vaccines		135,918		130,554
	Total Revenues	$	6,832,588	$	5,530,741
	Cost of Revenues
	Micro-organism	$	683,784	$	587,417
	Veterinary Medications		3,033,027		2,105,516
	Feed Additives		220,148		214,637
	Vaccines		72,444		23,316
	Total Cost of Revenues		4,009,403		2,930,886
	Gross Profit	$	2,823,185	$	2,599,855

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles (“U.S. GAAP”) applicable to interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (which include all significant normal and recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for all periods presented have been made. The accompanying results of operations are not necessarily indicative of the operating results that may be expected for the entire year ending December 31, 2014. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and accompanying notes thereto of the Company, which are included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013 filed with the Securities and Exchange Commission (“SEC”).
Consolidation, Policy [Policy Text Block]	'
	Principles of consolidation
	The accompanying condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. The consolidated financial statements include the financial statements of the Company, its wholly-owned subsidiaries, and its variable interest entities (“VIEs”).  All significant inter-company transactions and balances between the Company, its subsidiaries, and its VIEs have been eliminated in consolidation.
	The Company has evaluated the relationship with Xi’an Tianxing and Xi’an Tianxing’s wholly owned subsidiaries, Xi’an Sikaida and Shanghai Siqiang. As a result of the contractual arrangements which obligate Sida to absorb all of the risk of loss from Xi’an Tianxing’s activities and enable Sida to receive all of its expected residual returns, the Company is the primary beneficiary of these VIEs and thus it accounts for Xi’an Tianxing, Xi’an Sikaida and Shanghai Siqiang as VIEs under the Financial Accounting Standards Board’s (“FASB”) interpretation on consolidation of variable interest entities. Accordingly, the Company consolidates the results, assets, and liabilities of Xi’an Tianxing, Xi’an Sikaida and Shanghai Siqiang.
Use of Estimates, Policy [Policy Text Block]	'
	Use of estimates
	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The level of uncertainty in estimates and assumptions increases with the length of time to complete the underlying transactions. Actual results may differ from these estimates in amounts that may be material to the consolidated financial statements and accompanying notes. Significant estimates and assumptions made by the Company are used for, but not limited to the allowance for doubtful accounts, useful lives of property, plant and equipment and intangible assets, assumptions used in assessing impairment for long-lived assets and the fair value for derivative instruments.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	'
	Foreign currency translation
	The Company uses the United States dollar (“U.S. dollar”) for financial reporting purposes and the Chinese Renminbi (“RMB”) as its functional currency. The Company’s subsidiaries and VIEs maintain their books and records in their functional currency, being the primary currency of the economic environment in which their operations are conducted.
	The Company translates the subsidiaries’ and VIEs’ assets and liabilities into U.S. dollars using the applicable exchange rates prevailing at the balance sheet dates, and the statements of comprehensive income and cash flows are translated at average exchange rates during the reporting period. As a result, amounts related to assets and liabilities reported on the consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets. Equity accounts are translated at historical rates. Adjustments resulting from the translation of the subsidiaries’ and VIEs’ financial statements are recorded as accumulated other comprehensive income.
	The quotation of the exchange rates does not imply free convertibility of RMB to other foreign currencies. All foreign exchange transactions continue to take place either through the People’s Bank of China or other banks authorized to buy and sell foreign currencies at the exchange rate quoted by the People’s Bank of China.
	Approval of foreign currency payments by the People’s Bank of China or other institutions requires submitting a payment application form together with invoices, shipping documents, and signed contracts. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in the results of operations as incurred.
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair values of financial instruments
	ASC Topic 820, Fair Value Measurement and Disclosures , defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This topic also establishes a fair value hierarchy, which requires classification based on observable and unobservable inputs when measuring fair value. Certain current assets and current liabilities are financial instruments.  Management believes their carrying amounts are a reasonable estimate of fair value because of the short period of time between the origination of such instruments and their expected realization and, if applicable, their current interest rates are equivalent to interest rates currently available. The three levels of valuation hierarchy are defined as follows:
		¨	Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
		¨	Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.
		¨	Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.
	The following table sets forth by level within the fair value hierarchy our financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2014 and December 31, 2013:
			Carrying		Fair Value Measurement at
			Value at		March 31, 2014
			March 31,
			2014		Level 1		Level 2		Level 3
	Purchase option liability		$	78,960	$	—	$	78,960	$	—
			Carrying		Fair Value Measurement at
			Value at		December 31, 2013
			December 31,
			2013		Level 1		Level 2		Level 3
	Purchase option liability		$	62,440	$	—	$	62,440	$	—
	Below is the reconciliation for the purchase option liability changes from January 1, 2014 to March 31, 2014:
	Balance, January 1, 2014		$	62,440
	Change in fair value			16,520
	Balance, March 31, 2014		$	78,960
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue recognition
	Revenue of the Company is primarily derived from the sales of veterinary healthcare and medical care products in China. Sales are recognized when the following four revenue criteria are met: persuasive evidence of an arrangement exists, delivery has occurred, the selling price is fixed or determinable, and collectability is reasonably assured. Sales are presented net of value added tax (“VAT”). No estimated allowance for sales returns is reflected in these consolidated financial statements as sales returns historically have been insignificant.
	There are two types of sales upon which revenue is recognized:
		a.	Credit sales: revenue is recognized when the products have been delivered to the customers.
		b.	Full payment before delivery: Cash received is recorded as “deposits from customers” and revenue is recognized when the products have been delivered to the customers.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash
	Cash includes currency on hand and demand deposits with banks with an original maturity of three months or less.
Receivables, Policy [Policy Text Block]	'
	Accounts receivable
	Accounts receivable are stated at cost, net of an allowance for doubtful accounts. The Company maintains allowances for doubtful accounts for estimated losses, if any, resulting from the failure of customers to make required payments. The Company reviews the accounts receivable on a periodic basis and makes allowances where there is doubt as to the collectibility of individual balances. In evaluating the collectibility of individual receivable balances, the Company considers many factors, including the age of the balance, the customer’s payment history, its current credit-worthiness and current economic trends.
Inventory, Policy [Policy Text Block]	'
	Inventories
	Inventories are stated at the lower of cost as determined on a weighted-average basis, or market. Inventories include purchases and related costs incurred in bringing the inventories to their present location and condition. Management reviews inventories for obsolescence and cost in excess of net realizable value and records a write-down against the inventory and additional cost of goods sold when the carrying value exceeds net realizable value.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property, plant and equipment
	Property, plant and equipment are stated at cost less accumulated depreciation and impairment losses, if any. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Expenditures for maintenance and repairs that do not improve or extend the useful lives of the assets are charged to operations as incurred, while renewals and betterments are capitalized. Gains and losses on disposals are included in the results of operations. Estimated useful lives of the assets are as follows:
			Estimated useful life
	Buildings and improvements		Shorter of lease
			term or 10-40 years
	Machinery and equipment		5-10 years
	Office equipment and furniture		3-10 years
	Vehicles		5-10 years
	Management assesses the carrying value of property, plant and equipment annually or more often when factors indicating impairment are present, and reduces the carrying value of such assets by the amount of the impairment. The Company determines the existence of such impairment by measuring the expected future cash flows (undiscounted) and comparing such amount to the net asset carrying value. An impairment loss, if it exists, is measured as the amount by which the carrying amount of the asset exceeds the fair value of the asset. Based on its review, management believes that, as of March 31, 2014 and December 31, 2013, there was no impairment of its property, plant and equipment.
Construction In Progress Policy [Policy Text Block]	'
	Construction-in-progress
	Construction-in-progress includes direct costs of construction of factory buildings. Interest incurred during the period of construction, if significant, is capitalized. All other interest is expensed as incurred. Construction-in-progress is not depreciated until such time as the asset is completed and put into service.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	'
	Intangible assets
	Land use rights — Land use rights represent the amounts paid to acquire a long-term interest to utilize the land underlying the Company’s facilities. This type of arrangement is common for the use of land in the PRC. Land use rights are amortized on the straight-line method over the contractual lease terms.  The land use right granted to the Company’s Huxian facility was for 50 years.  The land use right granted to the Company’s Jingzhou facility was 30 years. The land use right granted to the Company’s Kunshan facility was for 41 years.
	Technological know-how — Purchased technological know-how includes confidential formulas, manufacturing processes, and technical and procedural manuals, and is amortized using the straight-line method over an estimated useful life of between five to eleven years that reflects the period over which such confidential formulas, manufacturing processes, and technical and procedural manuals are kept confidential by the Company as agreed between the Company and the selling parties.
	Impairment of intangible assets —Intangible assets are evaluated at least annually for impairment if events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Based on the existence of one or more indicators of impairment, the Company measures any impairment of long-lived assets by comparing the asset's estimated fair value with its carrying value, based on cash flow methodology. Based on its review, the Company believes that, as of March 31, 2014 and December 31, 2013, there was no impairment of its intangible assets.
Comprehensive Income, Policy [Policy Text Block]	'
	Comprehensive income
	Comprehensive income is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income is comprised of the foreign currency translation adjustments.
Shipping and Handling Cost, Policy [Policy Text Block]	'
	Shipping and handling costs
	Shipping and handling costs related to costs of goods sold are included in selling expenses, and totaled $192,048 and $203,849 for the three months ended March 31, 2014 and 2013, respectively.
Advertising Costs, Policy [Policy Text Block]	'
	Advertising costs
	Advertising costs are charged to selling expenses as incurred. Advertising costs were insignificant for both the quarters ended March 31, 2014 and 2013, respectively.
Research and Development Expense, Policy [Policy Text Block]	'
	Research and development costs
	Research and development costs are charged to expense as incurred and include salaries, professional fees, and technical support fees related to such efforts.
Income Tax, Policy [Policy Text Block]	'
	Income taxes
	The Company accounts for income taxes using an asset and liability method.  Under this method, deferred income taxes are recognized for the tax consequences of temporary differences by applying enacted statutory tax rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. The effect on deferred income taxes of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or all of a deferred tax asset will not be realized.
	A tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. As of March 31, 2014 and December 31, 2013, there are no unrecognized tax benefits, and the Company does not expect a significant change in tax benefits in the next 12 months.  Penalties and interest levied by taxing authorities, if any, are classified as income tax expense in the year incurred.  No significant penalties or interest relating to income taxes have been incurred during the three months ended March 31, 2014 and 2013.
	According to the PRC Tax Administration and Collection Law, the statute of limitations is three years if the underpayment of taxes is due to computational or other errors made by the taxpayer or the withholding agent.  The statute of limitations extends to five years under special circumstances. In the case of transfer pricing issues, the statute of limitations is ten years. There is no statute of limitations in the case of tax evasion. Accordingly, the income tax returns of the Company’s PRC operating subsidiaries for the years ended December 31, 2008 through 2013 are open to examination by the PRC state and local tax authorities.
Government Grants [Policy Text Block]	'
	Government grants
	The Company’s subsidiaries in China receive government subsidies from local Chinese government agencies in accordance with relevant Chinese government policies. In general, the Company presents the government subsidies received as part of other income unless the subsidies received are earmarked to compensate for a specific expense, which have been accounted for by offsetting the specific expense, such as research and development expense or interest expenses. Unearned government subsidies received are deferred for recognition until the criteria for such recognition could be met.
	For research and development expenses, the Company matches and offsets the government grants with the expenses of the research and development activities as specified in the grant approval document in the corresponding period when such expenses are incurred.
	No government grants were offset against the finance costs for the three months ended March 31, 2014 and 2013.
	Government grants of $154,902 and $nil were received and recognized as other income during the three months ended March 31, 2014 and 2013.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-based compensation
	The Company records and reports stock-based compensation by measuring the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which services are received. Stock compensation for stock granted to non-employees is determined as the fair value of the consideration received or the fair value of equity instruments issued, whichever is more reliably measured.
Earnings Per Share, Policy [Policy Text Block]	'
	Earnings per share
	Basic earnings per share is based upon the weighted-average number of common shares outstanding. Diluted earnings per share is based on the assumption that all dilutive convertible shares, including convertible preferred shares, warrants and stock options were converted or exercised. Further, the method requires that stock dividends or stock splits be accounted for retroactively if the stock dividends or stock splits occur during the period or after the end of the period but before the release of the financial statements, by considering it outstanding for the entirety of each period presented. Diluted earnings per share is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period.
Related Party [Policy Text Block]	'
	Related parties
	Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of such principal owners and management, and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.
Operating Segments [Policy Text Block]	'
	Operating segments
	While the chief operating decision-makers monitor the revenue streams of the various products lines, operations are managed and financial performance is evaluated on a Company-wide basis. Product lines are aggregated into one as operating results for all product lines are similar. Accordingly, all of the major product lines (micro-organism, veterinary medicine, feed additives and vaccines) are considered by management to be aggregated in one reportable operating segment.
	As the Company primarily generates its revenues from customers in the PRC, no geographical segments are presented.
Reclassification, Policy [Policy Text Block]	'
	Reclassification
	Certain amounts included in the 2013 consolidated statements of comprehensive income has been reclassified to conform to the 2014 financial statement presentation as follows;
	The Company has separately presented interest income of $148,845 on the face of consolidated statements of comprehensive income for the period ended March 31, 2013, instead of presenting it net of interest expenses.
	As a result of such reclassification, interest expense, net for the three months ended March 31, 2014, has changed from $40,547 to $189,392.
	The change in due to related parties of $201,325 was classified into cash flows from financing activities in the Company’s condensed consolidated statements of cash flows for the three months ended March 31, 2013. The Company has reclassified this amount as component of cash flows to operating activities.
	As a result of such reclassification, net cash provided by financing activities for the three months ended March 31, 2013 has changed from $2,591,125 to $2,389,800 and net cash used in operating activities has changed from $9,983,900 to $9,782,575.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recently issued accounting pronouncements
	In March 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2013-05, Foreign Currency Matters, (Topic 830): Parent's Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity (ASU 2013-05), to resolve a diversity in accounting for the cumulative translation adjustment of foreign currency upon derecognition of a foreign subsidiary or group of assets. ASU 2013-05 requires the parent to apply the guidance in Subtopic 830-30 to release any related cumulative translation adjustment into net income when a reporting entity (parent) ceases to have a controlling financial interest in a subsidiary or group of assets within a foreign entity. Accordingly, the cumulative translation adjustment should be released into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided. Further, ASU 2013-05 clarified that the parent should apply the guidance in subtopic 810-10 if there is a sale of an investment in a foreign entity, including both (1) events that result in the loss of a controlling financial interest in a foreign entity and (2) events that result in an acquirer obtaining control of an acquiree in which it held an equity interest immediately before the acquisition date. Accordingly, the cumulative translation adjustment should be released into net income upon the occurrence of those events. The Company adopted ASU 2013-05 prospectively in its first quarter of fiscal 2014, and it did not have a significant impact on its consolidated results of operations and financial condition.
	In July 2013, the FASB issued Accounting Standards Update No. 2013-11, Income Taxes (Topic 740) (ASU 2013-11). The amendments in this update provide guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, similar tax loss, or tax credit carryforward exists. These amendments provide that an unrecognized tax benefit, or a portion thereof, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except to the extent that a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date to settle any additional income taxes that would result from disallowance of a tax position, or the tax law does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, then the unrecognized tax benefit should be presented as a liability. The amendments in this update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption is permitted. The Company adopted ASU 2013-11 effective January 1, 2014 and it did not have a significant impact on its consolidated results of operations and financial condition.
	Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s consolidated financial statements upon adoption.

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	'
	The following table sets forth by level within the fair value hierarchy our financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2014 and December 31, 2013:
		Carrying		Fair Value Measurement at
		Value at		March 31, 2014
		March 31,
		2014		Level 1		Level 2		Level 3
	Purchase option liability	$	78,960	$	—	$	78,960	$	—
		Carrying		Fair Value Measurement at
		Value at		December 31, 2013
		December 31,
		2013		Level 1		Level 2		Level 3
	Purchase option liability	$	62,440	$	—	$	62,440	$	—
Schedule Of Reconciliation For Warrant Or Purchase Option Liabilities [Table Text Block]	'
	Below is the reconciliation for the purchase option liability changes from January 1, 2014 to March 31, 2014:
	Balance, January 1, 2014	$	62,440
	Change in fair value		16,520
	Balance, March 31, 2014	$	78,960
Schedule Of Estimated Useful Lives Of Assets [Table Text Block]	'
	Estimated useful lives of the assets are as follows:
		Estimated useful life
	Buildings and improvements	Shorter of lease
		term or 10-40 years
	Machinery and equipment	5-10 years
	Office equipment and furniture	3-10 years
	Vehicles	5-10 years

ACCOUNTS_RECEIVABLE_NET_Tables

ACCOUNTS RECEIVABLE, NET (Tables)	3 Months Ended
	Mar. 31, 2014
Accounts Receivable Disclosure [Abstract]	'
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	'
	Accounts receivable consisted of the following:
		March 31,		December 31,
		2014		2013
	Accounts receivable	$	13,624,127	$	11,611,741
	Allowance for doubtful accounts		-960,578		-602,243
	Accounts receivable, net	$	12,663,549	$	11,009,498
Schedule Of Movement In Allowance For Doubtful Accounts [Table Text Block]	'
	The following table presents the movement of the allowance for doubtful accounts:
	Balance, January 1, 2014	$	602,243
	Addition		366,218
	Recovery		—
	Translation adjustment		-7,883
	Balance, March 31, 2014	$	960,578

INVENTORIES_Tables

INVENTORIES (Tables)	3 Months Ended
	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
	Inventories consist of the following:
		March 31,		December 31,
		2014		2013
	Raw materials	$	21,970,441		23,001,461
	Packing materials		350,799		396,067
	Work-in-process		152,884		23,140
	Finished goods		2,717,505		2,409,083
	Other		74,154		73,835
	Total	$	25,265,783		25,903,586

DEPOSITS_PREPAID_EXPENSES_AND_1

DEPOSITS, PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)	3 Months Ended
	Mar. 31, 2014
Deposits and Prepaid Expenses Disclosure [Abstract]	'
Schedule Of Deposits and Prepaid Expenses [Table Text Block]	'
	Deposits, prepaid expenses and other receivables are comprised of the following:
		March 31,		December 31,
		2014		2013
	Other prepayments	$	365,055	$	478,144
	Deposits placed with guarantors (note 13)		486,900		491,100
	Interest receivable (notes 7 and 12)		168,718		497,844
	Other receivables		587,732		667,075
	Total	$	1,608,405	$	2,134,163

PREPAYMENTS_TO_SUPPLIERS_Table

PREPAYMENTS TO SUPPLIERS (Tables)	3 Months Ended
	Mar. 31, 2014
Prepayments For Raw Materials Purchasing [Abstract]	'
Prepayments For Raw Materials Purchasing [Table Text Block]	'
	Prepayments to suppliers are comprised of the following:
		March 31,		December 31,
		2014		2013
	Prepayments for raw materials	$	39,438,992	$	39,937,944
	Prepayments for packaging materials		1,102,483		1,123,200
	Total	$	40,541,475	$	41,061,144

PROPERTY_PLANT_AND_EQUIPMENT_N1

PROPERTY, PLANT AND EQUIPMENT, NET (Tables)	3 Months Ended
	Mar. 31, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Property, plant and equipment consist of the following:
		March 31,		December 31,
		2014		2013
	Buildings and improvements	$	28,033,999	$	27,703,872
	Machinery and equipment		8,261,929		6,093,533
	Office equipment and furniture		334,800		337,688
	Vehicles		606,755		611,989
	Total		37,237,483		34,747,082
	Less: accumulated depreciation		-6,819,830		-6,477,927
	Plant and equipment, net	$	30,417,653	$	28,269,155

CONSTRUCTIONINPROGRESS_Tables

CONSTRUCTION-IN-PROGRESS (Tables)	3 Months Ended
	Mar. 31, 2014
Construction In Progress Disclosure [Abstract]	'
Schedule Of Construction In Progress [Table Text Block]	'
	The construction projects the Company was in the progress of completing are as follows:
		Total in CIP
		as of
	Project	March 31,		Estimated Cost to		Estimated		Estimated
		2014		Complete		Total Cost		Completion Date
	Jingzhou veterinary medication facility	$	1,203,130	$	501,020	$	1,704,150	Fourth quarter of 2014
	Kunshan micro-organism facility		5,267,642		7,241,039		12,508,681	Construction - completed, Installation of machinery and equipment – Third quarter of 2014
	Total	$	6,470,772	$	7,742,059	$	14,212,831

LONGTERM_PREPAYMENTS_Tables

LONG-TERM PREPAYMENTS (Tables)	3 Months Ended
	Mar. 31, 2014
Long Term Prepayments Disclosure [Abstract]	'
Schedule Of Long Term Prepayments [Table Text Block]	'
	Long-term prepayments consist of the following:
		March 31,		December 31,
		2014		2013
	Deposits for equipment purchase and land use rights	$	3,836,884	$	3,871,228
	Construction deposits		386,224		366,688
	Prepayments for R&D project		363,552		389,556
	Deposits for other		6,091		6,142
	Long-term prepayments	$	4,592,751	$	4,633,614
	Long-term prepayments for acquisitions	$	-	$	183,344

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Finite-Lived Intangible Assets [Table Text Block]	'
	Intangible assets consist of the following:
		March 31,		December 31,
		2014		2013
	Land use rights	$	4,909,577	$	4,951,927
	Technological know-how		2,596,800		2,619,200
	Total		7,506,377		7,571,127
	Less: accumulated amortization		-2,375,923		-2,333,872
	Intangible assets, net	$	5,130,454	$	5,237,255
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	Amortization expense expected for the next five years and thereafter is as follows:
	Years ending December 31,	Amount
	2014	$	186,032
	2015		248,042
	2016		248,042
	2017		248,042
	2018		248,042
	Thereafter		3,952,254
	Total	$	5,130,454

SHORTTERM_LOANS_Tables

SHORT-TERM LOANS (Tables)	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Schedule Of Outstanding Short-Term Loans [Table Text Block]	'
	Outstanding short-term loans consisted of the following:
			March 31, 2014				December 31, 2013					Interest
	Bank		Amt RMB		Amt USD		Amt RMB		Amt USD		Due Date	Rate
	Industrial Bank Co. Ltd. Xi’an Branch			-	$	-		30,000,000	$	4,911,000	1/15/14		6.6	%
	Postal Savings Bank of China Xi’an Branch			20,000,000		3,246,000		20,000,000		3,274,000	5/26/14		-2
	ICBC Songzi Branch			5,000,000		811,500		5,000,000		818,500	6/19/14		-1
	Related-party Individual – Chairman and CEO			10,000,000		1,623,000		10,000,000		1,637,000	9/11/14		7.8	%
	Total			35,000,000	$	5,680,500		65,000,000	$	10,640,500
		-1	People's Bank of China floating benchmark lending rate over the same period plus 30%, which was 7.8% at March 31, 2014.
		-2	People's Bank of China floating benchmark lending rate over the same period plus 20%, which was 7.2% at March 31, 2014.

CAPITAL_TRANSACTIONS_Tables

CAPITAL TRANSACTIONS (Tables)	3 Months Ended
	Mar. 31, 2014
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]	'
Schedule of Nonvested Share Activity [Table Text Block]	'
	A summary of changes in the Company’s non-vested shares for the year follows:
		Non-vested Shares
	Non-vested at January 1, 2013		6,000
	Granted		69,556
	Vested		-62,556
	Forfeited		-
	Non-vested at December 31, 2013		13,000
	Granted		50,000
	Vested		-21,500
	Forfeited		-
	Non-vested at March 31, 2014		41,500
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
	Outstanding purchase options do not trade in an active securities market, and as such, the Company estimates the fair value of these purchase options using the Black-Scholes Option Pricing Model (“Black-Scholes Model”) using the following assumptions:
		Purchase Options
		March 31,				December 31,
		2014				2013
	Stock price	$	6.56			$	3.51
	Exercise price	$	8.11			$	8.11
	Annual dividend yield		-				-
	Expected term (years)		0.25				0.5
	Risk-free interest rate		0.05	%			0.1	%
	Expected volatility		80	%			125	%
	Option value	$	0.56			$	0.45
Schedule Of Share Based Compensation Warrants and Purchase Options Activity [Table Text Block]	'
	Following is an activity summary of the Company’s outstanding purchase options:
		Number of			Weighted –			Weighted-
		purchase			average			average
		options			exercise price			remaining
								contractual term
								(Year)
	Outstanding at January 1, 2014		140,000		$	8.11			0.5
	Granted		-			-
	Forfeited		-			-
	Exercised		-			-
	Outstanding at March 31, 2014		140,000		$	8.11			0.25
	Exercisable at March 31, 2014		140,000		$	8.11			0.25

TAXES_Tables

TAXES (Tables)	3 Months Ended
	Mar. 31, 2014
Taxes Disclosure [Abstract]	'
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	'
	Provision for income taxes consisted of the following:
			Three months ended March 31,
	PRC income taxes		2014			2013
	Current		$	472,407		$	321,284
	Deferred			-42,380			-
	Total		$	430,027		$	321,284
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
	The following table reconciles the U.S. statutory rates to the Company’s effective tax rate for the three months ended March 31, 2014 and 2013:
			Three Months ended March 31,
			2014			2013
	U.S. statutory rate		34	%		34	%
	Foreign income not recognized in the U.S.		-34			-34
	China income tax rate		25			25
	China income tax exemption		-10			-10
	Other items (1)		15.6			16.1
	Total provision for income taxes		30.6	%		31.1	%
		-1	Other items are primarily for operating expenses (income) incurred by Skystar that are not deductible (taxable) in the PRC, expenses incurred by other subsidiaries that are not deductible on the consolidated level, the difference of taxable income under US GAAP rather than Chinese GAAP, and the difference of Enterprise Income Tax imposed at a statutory rate of 25% rather than preferential tax rate of 15% on the income from the subsidiaries other than Xi’an Tianxing, which resulted in an increase in the effective tax rate of 15.6% and 16.1% for the three months ended March 31, 2014 and 2013, respectively.
Income Tax Rate Reconciliation Other Adjustments [Table Text Block]	'
		Other items consisted of the following:
			Three Months ended March 31,
			2014		2013
	Income taxed at Chinese statutory rate of 25%		1.3	%	1	%
	Valuation allowance on tax loss		8.3		9.9
	Share based compensation		0.6		0.1
	Non-deductible operating expenses		5.4		5.1
	Total other items		15.6	%	16.1	%
Schedule Of Taxes Payable [Table Text Block]	'
	Taxes payable consisted of the following:
			March 31,			December 31,
			2014			2013
	Income taxes		$	1,126,025		$	662,811
	Value added taxes			1,526,475			576,603
	Other taxes			200,344			76,072
	Total		$	2,852,844		$	1,315,486

EARNINGS_PER_SHARE_Tables

EARNINGS PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
	The following is the calculation of earnings per share:
		Three months ended March 31,
		2014		2013
	Net income	$	975,450	$	712,733
	Weighted average shares used in basic computation		7,676,268		7,613,712
	Effect of dilutive potential non-vested common shares		24,466		-
	Weighted average shares used in diluted computation		7,700,734		7,613,712
	Earnings per share:
	Basic	$	0.13	$	0.09
	Diluted	$	0.13	$	0.09

RELATED_PARTY_TRANSACTIONS_AND1

RELATED PARTY TRANSACTIONS AND ARRANGEMENTS (Tables)	3 Months Ended
	Mar. 31, 2014
Related Party Transactions [Abstract]	'
Schedule of Related Party Transactions [Table Text Block]	'
	Amounts payable to related parties are summarized as follows:
			March 31,		December 31,
			2014		2013
	Amounts due to related parties
	Weibing Lu – CEO (1)		$	1,155,155	$	857,012
	Bing Mei – CFO (3)			92,209		41,283
	Scott Cramer – non-executive director and shareholder (2)			530,349		300,203
	Directors, shareholders and other related parties (4)			184,525		163,050
	Total		$	1,962,238	$	1,361,548
		-1	As of March 31, 2014 and December 31, 2013, the Company had unpaid reimbursement, compensation, and advances for business expenses due to Weibing Lu valued at $1,155,155 and $857,012, respectively.
		-2	As of March 31, 2014 and December 31, 2013, the Company had unpaid reimbursement and compensation due to Scott Cramer valued at $530,349 and $300,203, respectively. On March 10, 2014, the Board of Directors, including all of the independent members of the Board, reviewed and approved the terms of Mr. Cramer’s Consulting Services Agreement with the Company pursuant to which the Company would continue employing him as its US representative in consideration of (i) a quarterly cash fee of $7,500, (ii) 7,000 restricted shares of the Company’s common stock issuable on a quarterly basis pursuant to the Company’s 2010 Stock Incentive Plan (note 15), and (iii) reimbursement of out of pocket expenses.  In addition, Mr. Cramer agreed to pay certain invoices of the Company to its vendors (and the Company agreed to reimburse Mr. Cramer) in the form of a no interest bearing loan in the aggregate amount of approximately $250,000.
		-3	As of March 31, 2014 and December 31, 2013, the Company had unpaid reimbursement and compensation due to Bing Mei valued at $92,209 and $41,283, respectively.
		-4	The amounts due to directors, shareholders and other related parties at March 31, 2014 and December 31, 2013 include unpaid reimbursement and advances to other related parties for business expenses.

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	The minimum future lease payments for the next five years and thereafter are as follows:
	Period	Unrelated third		Related parties		Total
		parties
	Year ending December 31, 2014	$	25,761	$	46,742	$	72,503
	Year ending December 31, 2015		8,764		52,585		61,349
	Year ending December 31, 2016		8,764		52,585		61,349
	Year ending December 31, 2017 and thereafter		2,191		13,633		15,824
	Total	$	45,480	$	165,545	$	211,025
Schedule Of Research and Development Project Costs [Table Text Block]	'
	R&D projects are summarized as follows:
	Project	Amount		Amount		Total amount
		incurred as		expected to be		of
		of 03/31/2014		incurred		project
	Project with Northwestern Agricultural Technology University
	Application of nano-technology in the prevention of major milk cow disease	$	568,050	$	81,150	$	649,200
	Project with the Fourth Military Medical University
	Fish diseases linked immunosorbent detection kit and fish diseases Multi-linked monoclonal antibody therapeutic agents		843,960		129,840		973,800
	New treatment and diagnosis method for Mycoplasmal pneumonia of swine		243,450		81,150		324,600
	In-house R&D projects during 2012:
	Oral liquid products R&D and field trials		162,300		-		162,300
	Powder for injection products R&D and field trials		162,300		-		162,300
	Vitamin E injection product development		81,150		-		81,150
	Anthelmintic product development		81,150		-		81,150
	Three disease grams product development		81,150		-		81,150
	Premixes class product development		81,150		-		81,150
	Bulk powder products development		81,150		-		81,150
	Livestock and fish diseases immunoassay kit development		405,750		-		405,750
	In-house R&D projects during 2013:
	Fish monoclonal antibody vaccine		486,900		81,150		568,050
	Livestock and avian disease multi-joint yolk antibody therapeutic agents		324,600		389,520		714,120
	Other projects for veterinary products formula adjustment, pet drug development, fermentation engineering design and development, GMP inspection trial production tests and other lab tests		1,665,948		16,230		1,682,178
	Total	$	5,269,008	$	779,040	$	6,048,048
Long-term Purchase Commitment [Table Text Block]	'
	The Company’s commitments for capital expenditure as of March 31, 2014 are as follows:
	Contracted but not accrued for:
	Purchase of machinery and construction (Note 9)	$	4,321,562

SEGEMENT_INFORMATION_Tables

SEGEMENT INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	The Company’s revenues and cost of revenues by product line were as follows:
		Three Months Ended
		March 31,
		2014		2013
	Revenues
	Micro-organism	$	1,521,165	$	1,667,182
	Veterinary Medications		4,844,968		3,446,717
	Feed Additives		330,537		286,288
	Vaccines		135,918		130,554
	Total Revenues	$	6,832,588	$	5,530,741
	Cost of Revenues
	Micro-organism	$	683,784	$	587,417
	Veterinary Medications		3,033,027		2,105,516
	Feed Additives		220,148		214,637
	Vaccines		72,444		23,316
	Total Cost of Revenues		4,009,403		2,930,886
	Gross Profit	$	2,823,185	$	2,599,855

ORGANIZATION_Details_Textual

ORGANIZATION (Details Textual)	Apr. 21, 2010	Apr. 21, 2010	Apr. 21, 2010	Apr. 21, 2010	7-May-10	Mar. 15, 2011	Mar. 15, 2011	Feb. 05, 2010	Feb. 05, 2010
	Xian Tianxing [Member]	Xian Tianxing [Member]	Kunshan Sikeda Biotechnology Co Ltd [Member]	Kunshan Sikeda Biotechnology Co Ltd [Member]	Skystar Biotechnology (Kunshan) Co., Limited [Member]	Xian Sikaida Bio-products Co., Ltd. [Member]	Xian Sikaida Bio-products Co., Ltd. [Member]	Skystar Biotechnology (Jingzhou) Co., Limited [Member]	Skystar Biotechnology (Jingzhou) Co., Limited [Member]
	USD ($)	CNY	USD ($)	CNY	USD ($)	USD ($)	CNY	USD ($)	CNY
Organization [Line Items]	'	'	'	'	'	'	'	'	'
Capital	$40,575	250,000	$81,150	500,000	$15,000,000	$1,623,000	10,000,000	$4,200,000	26,000,000
Capital Required to be Well Capitalized	'	'	'	'	12,750,000	'	'	'	'
Capital Contribution In Cash	'	'	'	'	$2,250,000	'	'	'	'

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Purchase option liability	$78,960	$62,440
Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Purchase option liability	0	0
Fair Value, Inputs, Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Purchase option liability	78,960	62,440
Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Purchase option liability	$0	$0

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) (USD $)	3 Months Ended
	Mar. 31, 2014
Purchase Option Liability [Line Items]	'
Balance, January 1, 2014	$62,440
Change in fair value	16,520
Balance, March 31, 2014	$78,960

SUMMARY_OF_SIGNIFICANT_ACCOUNT5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)	3 Months Ended
	Mar. 31, 2014
Building and Building Improvements [Member] | Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated Useful Life	'10 years
Building and Building Improvements [Member] | Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated Useful Life	'40 years
Machinery and Equipment [Member] | Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated Useful Life	'5 years
Machinery and Equipment [Member] | Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated Useful Life	'10 years
Office equipment and furniture [Member] | Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated Useful Life	'3 years
Office equipment and furniture [Member] | Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated Useful Life	'10 years
Vehicles [Member] | Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated Useful Life	'5 years
Vehicles [Member] | Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated Useful Life	'10 years

SUMMARY_OF_SIGNIFICANT_ACCOUNT6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Significant Accounting Policies [Line Items]	'	'
Shipping, Handling and Transportation Costs	$192,048	$203,849
Interest Income, Other	170,665	148,845
Other Nonoperating Income (Expense)	154,919	-187
Increase (Decrease) in Due to Related Parties, Total	'	201,325
Net Cash Provided by (Used in) Financing Activities, Continuing Operations, Total	-4,905,600	2,389,800
Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total	4,597,282	-9,782,575
Percentage Of Income Tax Examination Minimum Likelihood Of Tax Benefits Being Realized Upon Settlement	50.00%	'
Government Grants [Member]	'	'
Significant Accounting Policies [Line Items]	'	'
Other Nonoperating Income (Expense)	154,902	0
Scenario, Previously Reported [Member]	'	'
Significant Accounting Policies [Line Items]	'	'
Other Nonoperating Income (Expense)	40,547	'
Interest Expense	189,392	'
Net Cash Provided by (Used in) Financing Activities, Continuing Operations, Total	'	2,591,125
Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total	'	$9,983,900
Land Use Right [Member] | Huxian Facility [Member]	'	'
Significant Accounting Policies [Line Items]	'	'
Finite-Lived Intangible Asset, Useful Life	'50 years	'
Land Use Right [Member] | Jingzhou Facility [Member]	'	'
Significant Accounting Policies [Line Items]	'	'
Finite-Lived Intangible Asset, Useful Life	'30 years	'
Land Use Right [Member] | Kunshan Facility [Member]	'	'
Significant Accounting Policies [Line Items]	'	'
Finite-Lived Intangible Asset, Useful Life	'41 years	'

CONCENTRATIONS_AND_CREDIT_RISK1

CONCENTRATIONS AND CREDIT RISK (Details Textual) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
			Supplier Concentration Risk [Member]	Supplier Concentration Risk [Member]	Product Concentration Risk [Member]	Product Concentration Risk [Member]
Concentration Risk [Line Items]	'	'	'	'	'	'
Concentration Risk, Percentage	'	'	71.00%	72.00%	32.00%	16.00%
Due To Related Parties, Current	$1,962,238	$1,361,548	'	'	$32,801,071	$32,094,767

ACCOUNTS_RECEIVABLE_NET_Detail

ACCOUNTS RECEIVABLE, NET (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Schedule of Financing Receivable [Line Items]	'	'
Accounts receivable	$13,624,127	$11,611,741
Allowance for doubtful accounts	-960,578	-602,243
Accounts receivable, net	$12,663,549	$11,009,498

ACCOUNTS_RECEIVABLE_NET_Detail1

ACCOUNTS RECEIVABLE, NET (Details 1) (USD $)	3 Months Ended
	Mar. 31, 2014
Schedule of Financing Receivable [Line Items]	'
Balance, January 1, 2014	$602,243
Addition	366,218
Recovery	0
Translation adjustment	-7,883
Balance, March 31, 2014	$960,578

INVENTORIES_Details

INVENTORIES (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Inventory [Line Items]	'	'
Raw materials	$21,970,441	$23,001,461
Packing materials	350,799	396,067
Work-in-process	152,884	23,140
Finished goods	2,717,505	2,409,083
Other	74,154	73,835
Total	$25,265,783	$25,903,586

DEPOSITS_PREPAID_EXPENSES_AND_2

DEPOSITS, PREPAID EXPENSES AND OTHER RECEIVABLES (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Deposits and Prepaid Expenses [Line Items]	'	'
Other prepayments	$365,055	$478,144
Deposits placed with guarantors (note 13)	486,900	491,100
Interest receivable (notes 7 and 12)	168,718	497,844
Other receivables	587,732	667,075
Total	$1,608,405	$2,134,163

PREPAYMENTS_TO_SUPPLIERS_Detai

PREPAYMENTS TO SUPPLIERS (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Payments To Suppliers [Line Items]	'	'
Prepayments for raw materials	$39,438,992	$39,937,944
Prepayments for packaging materials	1,102,483	1,123,200
Total	$40,541,475	$41,061,144

PREPAYMENTS_TO_SUPPLIERS_Detai1

PREPAYMENTS TO SUPPLIERS (Details Textual) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Payments To Suppliers [Line Items]	'	'	'
Unpaid interest income on prepayments to suppliers	$162,205	$118,182	'
Payments to Suppliers	32,199,192	'	31,953,084
Interest Rate Charged Annually On Prepayment On Raw Material	2.00%	'	2.00%
Unpaid Balance To Supplier	$160,995	'	$497,844

PROPERTY_PLANT_AND_EQUIPMENT_N2

PROPERTY, PLANT AND EQUIPMENT, NET (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Buildings and improvements	$28,033,999	$27,703,872
Machinery and equipment	8,261,929	6,093,533
Office equipment and furniture	334,800	337,688
Vehicles	606,755	611,989
Total	37,237,483	34,747,082
Less: accumulated depreciation	-6,819,830	-6,477,927
Plant and equipment, net	$30,417,653	$28,269,155

PROPERTY_PLANT_AND_EQUIPMENT_N3

PROPERTY, PLANT AND EQUIPMENT, NET (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'	'
Depreciation	$400,291	$313,561	'
Property, Plant and Equipment Pledged Against Loan	$3,191,746	'	$19,969,335

CONSTRUCTIONINPROGRESS_Details

CONSTRUCTION-IN-PROGRESS (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Construction In Progress [Line Items]	'	'
Total in CIP as of March 31,2014	$6,470,772	$9,284,947
Estimate Cost to Complete	7,742,059	'
Estimated Total Cost	14,212,831	'
Jingzhou Veterinary Medication Facility [Member]	'	'
Construction In Progress [Line Items]	'	'
Total in CIP as of March 31,2014	1,203,130	'
Estimate Cost to Complete	501,020	'
Estimated Total Cost	1,704,150	'
Estimated Completion Date	'Fourth quarter of 2014	'
Kunshan Micro Organism Facility [Member]	'	'
Construction In Progress [Line Items]	'	'
Total in CIP as of March 31,2014	5,267,642	5,267,642
Estimate Cost to Complete	7,241,039	'
Estimated Total Cost	$12,508,681	'
Estimated Completion Date	'Construction - completed, Installation of machinery and equipment – Third quarter of 2014	'

CONSTRUCTIONINPROGRESS_Details1

CONSTRUCTION-IN-PROGRESS (Details Textual) (USD $)	3 Months Ended			3 Months Ended					3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2014	Dec. 31, 2011	Mar. 31, 2014	Dec. 31, 2011	Mar. 31, 2014	Dec. 31, 2013
				Huxian Vaccine Facility [Member]	Huxian Animal Laboratory [Member]	Huxian Animal Laboratory [Member]	Jingzhou Facility [Member]	Jingzhou Facility [Member]	Kunshan Micro Organism Facility [Member]	Kunshan Micro Organism Facility [Member]
Construction In Progress [Line Items]	'	'	'	'	'	'	'	'	'	'
Total in cost in progress	$6,470,772	'	$9,284,947	'	'	$324,600	$1,203,130	$1,704,150	$5,267,642	$5,267,642
Payments to Acquire Machinery and Equipment	'	'	'	2,462,966	324,600	'	'	'	3,482,958	'
Purchase Price of Machinery And Equipment	'	'	'	'	'	'	'	'	7,303,500	'
Interest Costs Capitalized	$53,195	$0	'	'	'	'	'	'	'	'

LONGTERM_PREPAYMENTS_Details

LONG-TERM PREPAYMENTS (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Long Tem Prepayments [Line Items]	'	'
Deposits for equipment purchase and land use rights	$3,836,884	$3,871,228
Construction deposits	386,224	366,688
Prepayments for R&D project	363,552	389,556
Deposits for other	6,091	6,142
Long-term prepayments	4,592,751	4,633,614
Long-term prepayments for acquisitions	$0	$183,344

LONGTERM_PREPAYMENTS_Details_T

LONG-TERM PREPAYMENTS (Details Textual) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Long Tem Prepayments [Line Items]	'	'
Long-term prepayments for acquisitions	$0	$183,344

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Total	$7,506,377	$7,571,127
Less: accumulated amortization	-2,375,923	-2,333,872
Intangible assets, net	5,130,454	5,237,255
Land Use Rights [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Total	4,909,577	4,951,927
Technical Know How [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Total	$2,596,800	$2,619,200

INTANGIBLE_ASSETS_Details_1

INTANGIBLE ASSETS (Details 1) (USD $)	Dec. 31, 2013
Intangible Assets Future Amortization Expense [Line Items]	'
2014	$186,032
2015	248,042
2016	248,042
2017	248,042
2018	248,042
Thereafter	3,952,254
Total	$5,130,454

INTANGIBLE_ASSETS_Details_Text

INTANGIBLE ASSETS (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Dec. 31, 2013
			Use Rights [Member]	Use Rights [Member]
Intangible Assets [Line Items]	'	'	'	'
Amortization	$62,477	$60,872	'	'
Real Estate and Accumulated Depreciation, Carrying Amount of Land	'	'	$1,136,461	$1,529,960

LOANS_RECEIVABLE_Details_Textu

LOANS RECEIVABLE (Details Textual)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2014	Jan. 02, 2014	Jan. 02, 2014	Dec. 31, 2013	Mar. 31, 2014
	USD ($)	CNY	USD ($)	CNY	USD ($)	Prepaid Expenses and Other Current Assets [Member]
						USD ($)
Loans Receivables [Line Items]	'	'	'	'	'	'
Notes Receivable Stated Interest Rate	'	'	6.00%	6.00%	'	'
Notes, Loans and Financing Receivable, Net, Current	$1,046,835	6,450,000	$1,298,400	8,000,000	$0	'
Interest and Fee Income, Loans and Leases, Total	7,781	'	'	'	'	'
Interest Payable	'	'	'	'	'	$7,723

SHORTTERM_LOANS_Details

SHORT-TERM LOANS (Details)

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2013

Apr. 16, 2013

Apr. 16, 2013

Apr. 14, 2014

Apr. 14, 2014

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2013

Jan. 16, 2013

Jan. 16, 2013

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2013

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

Changan Bank [Member]

Changan Bank [Member]

Industrial Bank Co Ltd Xian Branch [Member]

Industrial Bank Co Ltd Xian Branch [Member]

Industrial Bank Co Ltd Xian Branch [Member]

Industrial Bank Co Ltd Xian Branch [Member]

Industrial Bank Co Ltd Xian Branch [Member]

Industrial Bank Co Ltd Xian Branch [Member]

Postal Savings Bank of China Xi'an Branch [Member]

Postal Savings Bank of China Xi'an Branch [Member]

Postal Savings Bank of China Xi'an Branch [Member]

Postal Savings Bank of China Xi'an Branch [Member]

Icbc Songzi Branch Two [Member]

Icbc Songzi Branch Two [Member]

Icbc Songzi Branch Two [Member]

Icbc Songzi Branch Two [Member]

Related-party Individual - Chairman and CEO [Member]

Related-party Individual - Chairman and CEO [Member]

Related-party Individual - Chairman and CEO [Member]

Related-party Individual - Chairman and CEO [Member]

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

Short-term Debt [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Bank Loans

$5,680,500

35,000,000

$10,640,500

65,000,000

$324,600

2,000,000

$7,790,400

48,000,000

$0

0

$4,911,000

30,000,000

$4,869,000

30,000,000

$3,246,000

[1]

20,000,000

[1]

$3,274,000

[1]

20,000,000

[1]

$811,500

[2]

5,000,000

[2]

$818,500

[2]

5,000,000

[2]

$1,623,000

10,000,000

$1,637,000

10,000,000

Due Date

'

'

'

'

'

'

'

'

15-Jan-14

15-Jan-14

'

'

'

'

26-May-14

[1]

26-May-14

[1]

'

'

19-Jun-14

[2]

19-Jun-14

[2]

'

'

11-Sep-14

11-Sep-14

'

'

Interest Rate

'

'

'

'

'

'

3.00%

3.00%

6.60%

6.60%

'

'

6.60%

6.60%

'

'

'

'

'

'

'

'

7.80%

7.80%

'

'

[1]

People's Bank of China floating benchmark lending rate over the same period plus 20%, which was 7.2% at March 31, 2014.

[2]

People's Bank of China floating benchmark lending rate over the same period plus 30%, which was 7.8% at March 31, 2014.

SHORTTERM_LOANS_Details_Textua

SHORT-TERM LOANS (Details Textual)

3 Months Ended

1 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

0 Months Ended

3 Months Ended

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Apr. 16, 2013

Apr. 16, 2013

Apr. 21, 2014

Apr. 21, 2014

Apr. 14, 2014

Apr. 14, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 21, 2014

Apr. 21, 2014

Apr. 14, 2014

Apr. 14, 2014

Mar. 31, 2014

Jun. 13, 2013

Jun. 13, 2013

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2013

Apr. 14, 2014

Apr. 14, 2014

Jun. 13, 2013

Jun. 13, 2013

Mar. 31, 2014

Jan. 16, 2013

Jan. 16, 2013

Apr. 16, 2013

Apr. 16, 2013

Mar. 31, 2014

Mar. 31, 2014

Apr. 16, 2013

Apr. 16, 2013

Mar. 31, 2014

Sep. 10, 2013

Sep. 10, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2013

Jan. 16, 2013

Jan. 16, 2013

USD ($)

CNY

USD ($)

CNY

USD ($)

USD ($)

CNY

Bankers Acceptance [Member]

Bankers Acceptance [Member]

Bankers Acceptance [Member]

Bankers Acceptance [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Construction in Progress [Member]

Industrial and Commercial Bank Of China Songzi Branch [Member]

Industrial and Commercial Bank Of China Songzi Branch [Member]

Industrial and Commercial Bank Of China Songzi Branch [Member]

Industrial and Commercial Bank Of China Songzi Branch [Member]

Industrial and Commercial Bank Of China Songzi Branch [Member]

Changan Bank [Member]

Changan Bank [Member]

Industrial and Commercial Bank Of China [Member]

Industrial and Commercial Bank Of China [Member]

Industrial and Commercial Bank Of China [Member]

Industrial and Commercial Bank Of China [Member]

Industrial and Commercial Bank Of China [Member]

Xian Taixin Investment Guarantee Co Ltd [Member]

Xian Taixin Investment Guarantee Co Ltd [Member]

Xian Taixin Investment Guarantee Co Ltd [Member]

Xian Taixin Investment Guarantee Co Ltd [Member]

Postal Savings Bank Of China Xi [Member]

Postal Savings Bank Of China Xi [Member]

Postal Savings Bank Of China Xi [Member]

Bank Of Beijing [Member]

Bank Of Beijing [Member]

Bank Of Beijing [Member]

Bank Of Beijing [Member]

Industrial Bank Co Ltd Xian Branch [Member]

Industrial Bank Co Ltd Xian Branch [Member]

Industrial Bank Co Ltd Xian Branch [Member]

Industrial Bank Co Ltd Xian Branch [Member]

Industrial Bank Co Ltd Xian Branch [Member]

Industrial Bank Co Ltd Xian Branch [Member]

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

Chairman And CEO [Member]

Chairman And CEO [Member]

Chairman And CEO [Member]

Chairman And CEO [Member]

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

Short Term And Long Term [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Bank Loans

$5,680,500

65,000,000

'

35,000,000

$10,640,500

$324,600

2,000,000

'

'

'

'

'

'

$7,790,400

48,000,000

$7,790,400

48,000,000

'

$811,500

5,000,000

'

'

'

$7,790,400

48,000,000

$811,500

5,000,000

'

$4,869,000

30,000,000

$324,600

2,000,000

$58,158

360,000

$3,246,000

20,000,000

'

'

'

'

'

$0

0

$4,911,000

30,000,000

$4,869,000

30,000,000

Interest Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.00%

3.00%

'

'

'

7.80%

'

'

3.00%

3.00%

30.00%

30.00%

7.80%

6.60%

6.60%

'

'

10.00%

10.00%

20.00%

20.00%

7.20%

7.80%

7.80%

'

'

6.60%

6.60%

'

'

6.60%

6.60%

Cash paid for interest

129,129

189,392

181,426

'

'

'

'

'

'

'

'

'

'

'

'

'

'

53,195

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fee Paid For Loan Guarantee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

81,150

500,000

'

81,150

500,000

'

'

'

'

'

'

'

58,158

360,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Description of Variable Rate Basis

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'People's Bank of China floating benchmark lending rate over the same period plus 30% of that rate

'People's Bank of China floating benchmark lending rate over the same period plus 30% of that rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'People's Bank of China floating benchmark lending rate over the same period plus 20% of that rate

'People's Bank of China floating benchmark lending rate over the same period plus 20% of that rate

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Collateral Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

162,300

1,000,000

'

'

'

'

'

'

Debt Instrument, Collateral

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'This loan is secured by the Companys buildings and land use rights in Jingzhou, Hubei Province.

'

'

'

'

'

'

'

'

'

'

'

'10% of the loan or $324,600 (RMB 2,000,000) is required to be kept by Xian Investment and Financing Guarantee Co., Ltd. to serve as collateral until the loan is repaid. This loan is secured by the Companys office buildings located in Xian

'10% of the loan or $324,600 (RMB 2,000,000) is required to be kept by Xian Investment and Financing Guarantee Co., Ltd. to serve as collateral until the loan is repaid. This loan is secured by the Companys office buildings located in Xian

'

'

'

'

'

'

'

'

'

'

'

'

'

Short-term Bank Loans and Notes Payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,623,000

10,000,000

162,300

1,000,000

'

'

'

'

'

'

Debt Instrument, Interest Rate Terms

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'People's Bank of China floating benchmark lending rate over the same period plus 30% of that rate

'

'

'

'

'

'

'

'

'

'period plus 30% of that rate, which was 7.8% at the date that the loan was issued.

'period plus 30% of that rate, which was 7.8% at the date that the loan was issued.

'

'

'

'

'

'

'

'

Debt Issuance Cost

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

29,434

180,000

'

'

'

'

'

'

Percentage Of Loan Served As Collateral Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

10.00%

'

'

'

'

'

'

Pledged Assets, Not Separately Reported, Real Estate

16,811,260

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Fee Amount

'

'

'

'

'

'

'

3,895

24,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest Expense, Short-term Borrowings, Total

129,129

'

189,392

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Bank Debt

'

'

'

'

'

'

'

'

'

'

'

7,790,400

48,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest Costs Capitalized

53,195

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deposit Assets, Total

'

'

'

'

'

'

'

'

'

$3,895,200

24,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument Fee Percentage

'

'

'

'

'

'

'

0.05%

0.05%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

DEFERRED_GOVERNMENT_GRANT_Deta

DEFERRED GOVERNMENT GRANT (Details Textual)	3 Months Ended			12 Months Ended	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
	Xian Municipal Government [Member]	Xian Municipal Government [Member]	Xian Municipal Government [Member]	Xian Municipal Government [Member]	Xian City Science and Technology Bureau [Member]	Xian City Science and Technology Bureau [Member]	Xian City Science and Technology Bureau [Member]
	USD ($)	CNY	USD ($)	USD ($)	USD ($)	CNY	USD ($)
Deferred Government Grant [Line Items]	'	'	'	'	'	'	'
Proceeds From Government Subsidies	$405,750	2,500,000	$409,250	'	'	'	'
Repayments Of Government Subsidies	681,660	4,200,000	687,540	'	'	'	'
Percentage Repayment Of Government Subsidies	70.00%	70.00%	'	'	'	'	'
Proceeds From Demand Payment	'	'	'	'	486,900	3,000,000	491,100
Proceeds from Interest Received	$194,760	1,200,000	'	$196,440	'	'	'

CAPITAL_TRANSACTIONS_Details

CAPITAL TRANSACTIONS (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Nonvested shares [Line Items]	'	'
Non-vested at January 1, 2013	13,000	6,000
Granted	50,000	69,556
Vested	-21,500	-62,556
Forfeited	0	0
Non-vested at Ending	41,500	13,000

CAPITAL_TRANSACTIONS_Details_1

CAPITAL TRANSACTIONS (Details 1) (Purchase Options [Member], USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Purchase Options [Member]	'	'
Purchase Options [Line Items]	'	'
Stock price	$6.56	$3.51
Exercise price	$8.11	$8.11
Annual dividend yield	0.00%	0.00%
Expected term (years)	'3 months	'6 months
Risk-free interest rate	0.05%	0.10%
Expected volatility	80.00%	125.00%
Option value	$0.56	$0.45

CAPITAL_TRANSACTIONS_Details_2

CAPITAL TRANSACTIONS (Details 2) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Purchase Options [Line Items]	'	'
Number of options purchase, Outstanding, beginning balance	140,000	'
Granted, Number of warrants/purchase options	0	'
Forfeited, Number of warrants/purchase options	0	'
Exercised, Number of warrants/purchase options	0	'
Number of options purchase, Outstanding, ending balance	140,000	140,000
Exercisable at March 31, 2014, Number of warrants/purchase options	140,000	'
Outstanding, Weighted - average exercise price, beginning balance	$8.11	'
Weighted Average Exercise Price Of Warrants And Purchase Options Granted Number	$0	'
Forfeited, Weighted - average exercise price	$0	'
Weighted Average Exercise Price Of Warrants And Purchase Options Exercised Number	$0	'
Outstanding, Weighted - average exercise price, ending balance	$8.11	$8.11
Exercisable at March 31, 2014, Weighted - average exercise price	$8.11	'
Weighted- average remaining contractual term, outstanding (Year)	'3 months	'6 months
Exercisable at March 31, 2014, Weighted - average remaining contractual term (Year)	'3 months	'

CAPITAL_TRANSACTIONS_Details_T

CAPITAL TRANSACTIONS (Details Textual) (USD $)

3 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Jun. 30, 2010

Mar. 31, 2014

Dec. 31, 2013

Dec. 08, 2009

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2013

4-May-12

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2012

Dec. 31, 2013

Mar. 31, 2013

26-May-09

Dec. 31, 2013

Dec. 31, 2012

Jul. 29, 2011

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2014

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 2 [Member]

Equity Compensation Plan 2010 [Member]

Equity Compensation Plan 2010 [Member]

Equity Compensation Plan 2010 [Member]

Equity Compensation Plan 2010 [Member]

Equity Compensation Plan 2010 [Member]

Non Executive Director [Member]

Non Executive Director [Member]

Non Executive Director [Member]

Non Executive Director [Member]

Non Executive Director [Member]

Director [Member]

Director [Member]

Director [Member]

Chief Financial Officer [Member]

Chief Financial Officer [Member]

Chief Financial Officer [Member]

Chief Financial Officer [Member]

Chief Executive Officer [Member]

Equity Compensation Plan 2010 [Member]

Equity Compensation Plan 2010 [Member]

Equity Compensation Plan 2010 [Member]

Equity Compensation Plan 2010 [Member]

Capital Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1

'

'

'

'

'

'

'

'

'

'

'

'

'

28,000

'

'

5,556

'

'

8,000

'

'

'

'

Fair Market Value Per Common Share

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.95

'

$1.73

'

'

'

$4.20

'

'

'

'

Closing Market Price Per Common Share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.20

$2.39

$2.17

$3.59

$1.37

$2.17

'

Share Based Compensation Number Of Share Issuable In Twelve Months Anniversary

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000

'

'

'

'

Share Based Compensation Number Of Share Issuable In Six Months Anniversary

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000

'

'

'

'

Common Stock Purchase Options Exercise Price

'

'

'

$8.11

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Purchase Options Outstanding

140,000

'

140,000

140,000

'

'

'

247,119

247,119

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

'

'

'

'

'

'

'

'

'

'

442,881

11,112

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

'

'

'

'

700,000

'

'

'

'

'

56,000

'

49,000

'

'

'

'

2,000

12,000

10,000

'

'

Unrecognized Compensation Cost

'

'

'

'

'

'

'

$138,198

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Change in fair value of purchase option liability

-16,520

4,466

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

'

'

'

'

140,000

140,000

'

59,725

'

4,340

'

'

'

'

'

'

'

'

'

'

50,000

'

'

'

Share Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Expected to Vest

12,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12,500

Share-based Compensation, Total

$59,725

$4,340

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested In Period

21,500

'

62,556

'

'

'

'

91,612

70,112

'

'

'

'

7,000

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,000

'

'

'

'

STATUTORY_RESERVES_Details_Tex

STATUTORY RESERVES (Details Textual)	Mar. 31, 2014
Statutory Reserves [Line Items]	'
Percentage Of Net Income To Be Set Aside On Annual Basis To Statutory Surplus Reserve Fund	10.00%
Maximum Percentage Of Statutory Surplus Reserve Over Entity's Registered Capital	50.00%

TAXES_Details

TAXES (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Income Tax Disclosure [Line Items]	'	'
Current	$472,407	$321,284
Deferred	-42,380	0
Total	$430,027	$321,284

TAXES_Details_1

TAXES (Details 1)	3 Months Ended
	Mar. 31, 2014		Mar. 31, 2013
Income Tax Disclosure [Line Items]	'		'
U.S. statutory rate	34.00%		34.00%
Foreign income not recognized in the U.S.	-34.00%		-34.00%
China income tax rate	25.00%		25.00%
China income tax exemption	-10.00%		-10.00%
Other items (1)	15.60%	[1]	16.10%	[1]
Total provision for income taxes	30.60%		31.10%
[1]	Other items are primarily for operating expenses (income) incurred by Skystar that are not deductible (taxable) in the PRC, expenses incurred by other subsidiaries that are not deductible on the consolidated level, the difference of taxable income under US GAAP rather than Chinese GAAP, and the difference of Enterprise Income Tax imposed at a statutory rate of 25% rather than preferential tax rate of 15% on the income from the subsidiaries other than Xiban Tianxing, which resulted in an increase in the effective tax rate of 15.6% and 16.1% for the three months ended March 31, 2014 and 2013, respectively.

TAXES_Details_2

TAXES (Details 2)	3 Months Ended
	Mar. 31, 2014		Mar. 31, 2013
Income Tax Disclosure [Line Items]	'		'
Income taxed at Chinese statutory rate of 25%	1.30%		1.00%
Valuation allowance on tax loss	8.30%		9.90%
Share based compensation	0.60%		0.10%
Non-deductible operating expenses	5.40%		5.10%
Total other items	15.60%	[1]	16.10%	[1]
[1]	Other items are primarily for operating expenses (income) incurred by Skystar that are not deductible (taxable) in the PRC, expenses incurred by other subsidiaries that are not deductible on the consolidated level, the difference of taxable income under US GAAP rather than Chinese GAAP, and the difference of Enterprise Income Tax imposed at a statutory rate of 25% rather than preferential tax rate of 15% on the income from the subsidiaries other than Xiban Tianxing, which resulted in an increase in the effective tax rate of 15.6% and 16.1% for the three months ended March 31, 2014 and 2013, respectively.

TAXES_Details_3

TAXES (Details 3) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Line Items]	'	'
Income taxes	$1,126,025	$662,811
Value added taxes	1,526,475	576,603
Other taxes	200,344	76,072
Total	$2,852,844	$1,315,486

TAXES_Details_Textual

TAXES (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Income Tax Disclosure [Line Items]	'	'	'
Foreign Income Tax Statutory Rate	25.00%	'	'
Foreign Preferential Tax Rate	15.00%	'	'
Effective Income Tax Rate Reconciliation, Nondeductible Expense	15.60%	16.10%	'
Operating Loss Carryforwards, Valuation Allowance	$1,723,589	'	$1,671,817
Undistributed Earnings Of Foreign Subsidiaries	52,900,000	'	50,900,000
Deferred Tax Assets, Net	403,372	'	364,425
Accrued Liabilities, Current	163,227	'	213,865
Allowance for Doubtful Accounts Receivable	240,145	'	150,560
U S Income Tax [Member]	'	'	'
Income Tax Disclosure [Line Items]	'	'	'
Operating Loss Carryforwards	5,069,380	'	4,917,108
P R C Income Tax [Member]	'	'	'
Income Tax Disclosure [Line Items]	'	'	'
Operating Loss Carryforwards	5,039,534	'	4,572,233
Operating Loss Carryforwards, Valuation Allowance	$1,259,883	'	$1,142,813

EARNINGS_PER_SHARE_Details

EARNINGS PER SHARE (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Earnings Per Share [Line Items]	'	'
Net income	$975,450	$712,733
Weighted average shares used in basic computation	7,676,268	7,613,712
Effect of dilutive potential non-vested common shares	24,466	0
Weighted average shares used in diluted computation	7,700,734	7,613,712
Earnings per share:	'	'
Basic (in dollars per share)	$0.13	$0.09
Diluted (in dollars per share)	$0.13	$0.09

EARNINGS_PER_SHARE_Details_Tex

EARNINGS PER SHARE (Details Textual)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Employee Stock Option [Member]	'	'
Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	140,000	140,000
Non Vested Shares [Member]	'	'
Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	'	4,000

RELATED_PARTY_TRANSACTIONS_AND2

RELATED PARTY TRANSACTIONS AND ARRANGEMENTS (Details) (USD $)	Mar. 31, 2014		Dec. 31, 2013
Related Party Transaction [Line Items]	'		'
Amounts due to related parties	$1,962,238		$1,361,548
Weibing Lu - Ceo [Member]	'		'
Related Party Transaction [Line Items]	'		'
Amounts due to related parties	1,155,155	[1]	857,012	[1]
Scott Cramer - Non-Executive Director And Shareholder [Member]	'		'
Related Party Transaction [Line Items]	'		'
Amounts due to related parties	530,349	[2]	300,203	[2]
Officer, Shareholder And Other Related Party [Member]	'		'
Related Party Transaction [Line Items]	'		'
Amounts due to related parties	184,525	[3]	163,050	[3]
Bing Mei Cfo [Member]	'		'
Related Party Transaction [Line Items]	'		'
Amounts due to related parties	$92,209	[4]	$41,283	[4]
[1]	As of March 31, 2014 and December 31, 2013, the Company had unpaid reimbursement, compensation, and advances for business expenses due to Weibing Lu valued at $1,155,155 and $857,012, respectively.
[2]	As of March 31, 2014 and December 31, 2013, the Company had unpaid reimbursement and compensation due to Scott Cramer valued at $530,349 and $300,203, respectively. On March 10, 2014, the Board of Directors, including all of the independent members of the Board, reviewed and approved the terms of Mr. Cramerbs Consulting Services Agreement with the Company pursuant to which the Company would continue employing him as its US representative in consideration of (i) a quarterly cash fee of $7,500, (ii) 7,000 restricted shares of the Companybs common stock issuable on a quarterly basis pursuant to the Companybs 2010 Stock Incentive Plan (note 15), and (iii) reimbursement of out of pocket expenses. In addition, Mr. Cramer agreed to pay certain invoices of the Company to its vendors (and the Company agreed to reimburse Mr. Cramer) in the form of a no interest bearing loan in the aggregate amount of approximately $250,000.
[3]	The amounts due to directors, shareholders and other related parties at March 31, 2014 and December 31, 2013 include unpaid reimbursement and advances to other related parties for business expenses.
[4]	As of March 31, 2014 and December 31, 2013, the Company had unpaid reimbursement and compensation due to Bing Mei valued at $92,209 and $41,283, respectively.

RELATED_PARTY_TRANSACTIONS_AND3

RELATED PARTY TRANSACTIONS AND ARRANGEMENTS (Details Textual) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Related Party Transaction [Line Items]	'	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period	50,000	69,556
Scott Cramer Non Executive Director and Shareholder [Member]	'	'
Related Party Transaction [Line Items]	'	'
Due to Related Parties, Total	530,349	300,203
Weibing Lu - Ceo [Member]	'	'
Related Party Transaction [Line Items]	'	'
Due to Related Parties, Total	1,155,155	857,012
Bing Mei Cfo [Member]	'	'
Related Party Transaction [Line Items]	'	'
Due to Related Parties, Total	92,209	41,283
US Representative [Member]	'	'
Related Party Transaction [Line Items]	'	'
Professional Fees	7,500	'
Reimbursement Payable	250,000	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period	7,000	'

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	Mar. 31, 2014
Future Minimum Payments [Line Items]	'
Year ending December 31, 2014	$72,503
Year ending December 31, 2015	61,349
Year ending December 31, 2016	61,349
Year ending December 31, 2017 and thereafter	15,824
Total	211,025
Unrelated third parties [Member]	'
Future Minimum Payments [Line Items]	'
Year ending December 31, 2014	25,761
Year ending December 31, 2015	8,764
Year ending December 31, 2016	8,764
Year ending December 31, 2017 and thereafter	2,191
Total	45,480
Related parties [Member]	'
Future Minimum Payments [Line Items]	'
Year ending December 31, 2014	46,742
Year ending December 31, 2015	52,585
Year ending December 31, 2016	52,585
Year ending December 31, 2017 and thereafter	13,633
Total	$165,545

COMMITMENTS_AND_CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details 1)

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2009

Dec. 31, 2009

Mar. 31, 2014

Mar. 31, 2014

Sep. 30, 2013

Sep. 30, 2013

Mar. 31, 2014

Mar. 31, 2014

Jun. 30, 2013

Jun. 30, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

USD ($)

Project With Northwestern Agricultural Technology University [Member]

Project With Northwestern Agricultural Technology University [Member]

Project With Fourth Military Medical University One [Member]

Project With Fourth Military Medical University One [Member]

Project With Fourth Military Medical University One [Member]

Project With Fourth Military Medical University One [Member]

Project With Fourth Military Medical University Two [Member]

Project With Fourth Military Medical University Two [Member]

Project With Fourth Military Medical University Two [Member]

Project With Fourth Military Medical University Two [Member]

Project With Fourth Military Medical University Three [Member]

Project With Fourth Military Medical University Three [Member]

Project With Fourth Military Medical University Three [Member]

Project With Fourth Military Medical University Three [Member]

In House R And D Project One [Member]

In House R And D Project Two [Member]

In House Rand D Project Three [Member]

In House R And D Project Four [Member]

In House R and D Project Five [Member]

In House R and D Project Six [Member]

In House R and D Project Seven [Member]

In House R and D Project Eight [Member]

In House R and D Project Nine [Member]

In House R and D Project Ten [Member]

In House R and D Project Eleven [Member]

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Commitments And Contingencies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount incurred as of 3/31/2014

$5,269,008

$568,050

3,500,000

$843,960

5,200,000

'

'

$243,450

1,500,000

'

'

$486,900

3,000,000

'

'

$162,300

$162,300

$81,150

$81,150

$81,150

$81,150

$81,150

$405,750

$486,900

$324,600

$1,665,948

Amount expected to be incurred

779,040

81,150

'

129,840

'

973,800

6,000,000

81,150

'

324,600

2,000,000

'

'

568,050

3,500,000

0

0

0

0

0

0

0

0

81,150

389,520

16,230

Total amount of project

$6,048,048

$649,200

'

$973,800

'

'

'

$324,600

'

'

'

'

'

'

'

$162,300

$162,300

$81,150

$81,150

$81,150

$81,150

$81,150

$405,750

$568,050

$714,120

$1,682,178

COMMITMENTS_AND_CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Details 2) (USD $)	3 Months Ended
	Mar. 31, 2014
Contracted but not accrued for:	'
Purchase of machinery and construction (Note 9)	$4,321,562

COMMITMENTS_AND_CONTINGENCIES_4

COMMITMENTS AND CONTINGENCIES (Details Textual)

Mar. 31, 2014

7-May-12

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2009

Dec. 31, 2009

Mar. 31, 2014

Mar. 31, 2014

Sep. 30, 2013

Sep. 30, 2013

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2008

Dec. 31, 2008

Apr. 15, 2013

Apr. 18, 2012

Apr. 18, 2012

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Jun. 30, 2013

Jun. 30, 2013

Mar. 31, 2014

Mar. 31, 2014

Jan. 01, 2007

Jan. 01, 2007

Jan. 31, 2012

Jan. 31, 2012

Mar. 31, 2014

Apr. 17, 2014

Apr. 15, 2013

Oct. 15, 2012

Oct. 15, 2012

Apr. 15, 2012

Apr. 15, 2012

Apr. 17, 2012

Apr. 17, 2012

Jul. 20, 2011

Jul. 20, 2011

Jul. 20, 2011

Mar. 31, 2014

Mar. 31, 2014

USD ($)

Skystar Biotechnology (Kunshan) Co., Limited [Member]

Related Parties [Member]

Related Parties [Member]

Unrelated Third Parties [Member]

Unrelated Third Parties [Member]

Project With Northwestern Agricultural Technology University [Member]

Project With Northwestern Agricultural Technology University [Member]

Project With Fourth Military Medical University One [Member]

Project With Fourth Military Medical University One [Member]

Project With Fourth Military Medical University One [Member]

Project With Fourth Military Medical University One [Member]

Project With Fourth Military Medical University Two [Member]

Project With Fourth Military Medical University Two [Member]

Project With Fourth Military Medical University Two [Member]

Project With Fourth Military Medical University Two [Member]

Veterinary Products Formula Adjustment Pet Drug Development and Fermentation Engineering Design and Development Project [Member]

Veterinary Products Formula Adjustment Pet Drug Development and Fermentation Engineering Design and Development Project [Member]

Project With Fourth Military Medical University [Member]

Project With Fourth Military Medical University [Member]

Jingzhou [Member]

Jingzhou [Member]

Jingzhou [Member]

Lantian County Chicken Farm [Member]

Lantian County Chicken Farm [Member]

Project With Fourth Military Medical University Three [Member]

Project With Fourth Military Medical University Three [Member]

Project With Fourth Military Medical University Three [Member]

Project With Fourth Military Medical University Three [Member]

Sanqiao Factory Premises [Member]

Sanqiao Factory Premises [Member]

Shanghai Siqiangs Office Space [Member]

Shanghai Siqiangs Office Space [Member]

Shanghai Siqiangs Office Space [Member]

Shanghai Siqiangs Office Space [Member]

Shanghai Siqiangs Office Space [Member]

Kunshan Office [Member]

Kunshan Office [Member]

Kunshan Office [Member]

Kunshan Office [Member]

Kunshan Office [Member]

Kunshan Office [Member]

Kunshan Office [Member]

Kunshan Office [Member]

Kunshan Office [Member]

Xian Warehouse Premises [Member]

Xian Warehouse Premises [Member]

Xian Warehouse Premises [Member]

Xian Warehouse Premises [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

Mr Weibing Lu [Member]

Mr Weibing Lu [Member]

Mr Weibing Lu [Member]

Mr Weibing Lu [Member]

Mr Weibing Lu [Member]

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

USD ($)

CNY

Commitments And Contingencies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Description of Lessee Leasing Arrangements, Operating Leases

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Company entered into a tenancy agreement for the lease of a sales office in Jingzhou, Hubei Province for a period of five years from April 18, 2012 to April 17, 2017

'

'

'

'

'

'

'

'

'Company entered into a tenancy agreement for the lease of factory premises of Xian Tianxing in Sanqiao for a period of ten years from October 1, 2004 to December 31, 2014. The annual rent for the factory premises is subject to a 10% increase every two years starting October 1, 2009

'Company entered into a tenancy agreement for the lease of factory premises of Xian Tianxing in Sanqiao for a period of ten years from October 1, 2004 to December 31, 2014. The annual rent for the factory premises is subject to a 10% increase every two years starting October 1, 2009

'

'

'

'

'Company also entered into a tenancy agreement with Mr. Weibing Lu for the lease of Shanghai Siqiangs office in Shanghai for a period of ten years from August 1, 2007 to August 1, 2017

'Company entered into an another one-year tenancy agreement for this office from April 15, 2014 to April 14, 2015

'Company entered into an another one-year tenancy agreement for this office from April 15, 2013 to April 14, 2014

'Company entered into a one year tenancy agreement for an office lease in Kunshan, Jiangsu Province from October 15, 2012 to April 14, 2013

'Company entered into a one year tenancy agreement for an office lease in Kunshan, Jiangsu Province from October 15, 2012 to April 14, 2013

'

'

'

'

'

'Company entered into a tenancy agreement for the lease of warehouse premises in Xian for a period of three years from July 20, 2011 to July 19, 2014

'Company entered into a tenancy agreement for the lease of warehouse premises in Xian for a period of three years from July 20, 2011 to July 19, 2014

'subject to a 10% increase every two years starting July 20, 2013

'subject to a 10% increase every two years starting July 20, 2013

Lease Expiration Date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

17-Apr-17

'

'

'

'

'

'

'

'

31-Dec-14

31-Dec-14

'

'

'

'

1-Aug-17

14-Apr-15

14-Apr-14

14-Apr-13

14-Apr-13

'

'

'

'

19-Jul-14

'

'

'

'

Operating Leases, Rent Expense

'

'

$13,245

$12,905

$18,921

$15,271

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$8,764

54,000

'

'

'

'

'

'

$22,780

140,360

$23,371

144,000

$29,214

180,000

'

'

'

$1,689

10,405

$3,820

23,536

$3,820

23,536

'

$38,141

235,000

$41,955

258,500

Clinical Research Stage

'

'

'

'

'

'

'

'

'

'

'

'

324,600

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

INCOME BEFORE PROVISION FOR INCOME TAXES

5,269,008

'

'

'

'

'

568,050

3,500,000

843,960

5,200,000

'

'

243,450

1,500,000

'

'

'

'

'

'

'

'

'

'

'

486,900

3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount expected to be incurred

779,040

'

'

'

'

'

81,150

'

129,840

'

973,800

6,000,000

81,150

'

324,600

2,000,000

1,665,948

10,264,620

649,200

4,000,000

'

'

'

714,120

4,400,000

'

'

568,050

3,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Investment Obligation Capital

'

$12,750,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

SEGEMENT_INFORMATION_Details

SEGEMENT INFORMATION (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Revenues	'	'
Total Revenues	$6,832,588	$5,530,741
Cost of Revenues	'	'
Total Cost of Revenues	4,009,403	2,930,886
Gross Profit	2,823,185	2,599,855
Veterinary Medications [Member]	'	'
Revenues	'	'
Total Revenues	4,844,968	3,446,717
Cost of Revenues	'	'
Total Cost of Revenues	3,033,027	2,105,516
Micro-organism [Member]	'	'
Revenues	'	'
Total Revenues	1,521,165	1,667,182
Cost of Revenues	'	'
Total Cost of Revenues	683,784	587,417
Feed Additives [Member]	'	'
Revenues	'	'
Total Revenues	330,537	286,288
Cost of Revenues	'	'
Total Cost of Revenues	220,148	214,637
Vaccines [Member]	'	'
Revenues	'	'
Total Revenues	135,918	130,554
Cost of Revenues	'	'
Total Cost of Revenues	$72,444	$23,316